The 4 th International Symposium of Training Plan for Oncology Professionals February 27 (Sat), 28 (Sun), 2016 Sheraton Miyako Hotel Osaka＂Main Hall Yamato-no-Ma＂ 6-1-55, Uehommachi, Tennoji-ku, Osaka 543-0001, JAPAN http://www.miyakohotels.ne.jp/osaka/english/
Hosted by 7-University Joint Project of Training Plan for Oncology Professionals
Supporters
Listed in no particular order
特定非営利活動法人 近畿がん診療推進ネットワーク
Chugai Pharmaceutical Co., Ltd.
Training Plan for Oncology Professionals gratefully acknowledges the generous support of organizations whose funding has made the 4th International Symposium possible. DAY 1 CONTENTS February 27 (Sat), 2016 4F Yamato no ma
Opening Ceremony ▶ 11:00 – 11:10 Moderator Toshio Shimizu, M.D., Ph.D., Tsutomu Iwasa, M.D., Ph.D., Takeshi Yoshida, M.D., Ph.D., Junko Tanizaki, M.D., Ph.D. (Department of Medical Oncology, Kinki University Faculty of Medicine)
Opening Remark Masayuki Iki, M.D., Ph.D. (Dean, Kinki University Faculty of Medicine)
Introduction Kazuhiko Nakagawa, M.D., Ph.D. (Professor, Department of Medical Oncology, Kinki University Faculty of Medicine)
Chugai Pharmaceutical Co., Ltd. Keynote Lecture ▶ 11:10 – 12:10 ...... 6 Chair: Tomoya Kawaguchi, M.D., Ph.D. (Associate Professor, Department of Respiratory Medicine, Graduate School of Medicine, Osaka City University) Kazuto Nishio, M.D., Ph.D. (Professor, Department of Genome Biology, Kinki University Faculty of Medicine)
Molecular correlative studies in randomized clinical studies of angiogenesis inhibitors.
Session 1 Radiation Oncology ▶ 12:40 – 14:00...... 8 Chair persons: Scott Bratman, M.D., Ph.D. (Princess Margaret Cancer Centre, Department of Radiation Oncology, University of Toronto, Canada) Ryohei Sasaki, M.D., Ph.D. (Kobe University) Masahiro Inada, M.D. (Kinki University) Mikoto Tamura (Kinki University) Jae Myung Noh, M.D. (Samsung Medical Center, Korea) Saki Osuga (Kobe University) Hiroshi Doi, M.D., Ph.D. (Hyogo College of Medicine)
Session 2 Oncology Nursing ▶ 14:05 – 15:00 ...... 13 Chair persons: Harue Arao, Ph.D., RN (Osaka University) Shizue Suzuki, Ph.D., RN (Kobe City College of Nursing) Hyunjin Jang, MSN, RN, OCN (Yonsei University, Korea) Sena Yamamoto, MSN, RN (Osaka University) Mie Soon In, RN, CRM (Seoul National University, Korea)
Session 3 Thoracic Oncology-１ ▶ 15:00 – 15:50...... 16 Chair persons: Toru Mukohara, M.D. (Kobe University) Kozo Kuribayashi, M.D. (Hyogo College of Medicine) Bin-Chi Liao, M.D. (National Taiwan University Hospital, Taiwan) Yoshihisa Kobayashi, M.D. (Kinki University) Satomi Watanabe, M.D. (Kinki University)
Poster Session-1 ▶ 15:50 – 17:30...... 19 Poster Viewing ▶ 15:50 – 16:20 Poster-1 Radiation Oncology ▶ 16:20 – 17:30 Chair persons: Hajime Monzen, M.D., Ph.D. (Kinki University) Masahiko Koizumi, M.D., Ph.D. (Osaka University) Yoshihito Nomoto, M.D.,Ph.D. (Mie University) Keita Yoshizaki (Osaka University) Yuhei Koike (Osaka University) Ryo Nishikawa, M.D. (Kobe University) Akinori Takada, M.D. (Mie University Hospital) Hitoshi Tatebe, M.D. (Kinki University) Takamasa Mitsuyoshi, M.D. (Kyoto University)
Welcome Reception ▶ 18:30 – 20:00 DAY 2 CONTENTS February 28 (Sun), 2016 4F Yamato no ma
Poster Session-2 ▶ 9:00 – 10:00
Poster-2 Hematological Oncology/Cancer Stem Cell ▶ 9:00 – 9:20...... 24 Chair: Hirohisa Nakamae, M.D., Ph.D. (Osaka City University) Tetsuya Takada (Kyoto Pharmaceutical University) Hideaki Yoshimura, M.D. (Kansai Medical University)
Poster-3 Developmental Therapeutics ▶ 9:20 – 9:40...... 25 Chair: Eishi Ashihara, M.D., Ph.D. (Kyoto Pharmaceutical University) Yuki Otani (Kyoto University Hospital) Yuka Asano, M.D. (Osaka City University)
Poster-4 Oncology Nursing ▶ 9:00 – 10:00...... 26 Chair persons: Koji Takeda, M.D. (Osaka City General Hospital) Kyoko Tanaka, Ph.D., RN (Osaka Prefecture University) Fumiko Koyama, MSN,RN (Kinki University Hospital) Daisuke Makiura (Kobe University Hospital) Kayo Inoue (Osaka University) Rieko Nakamura (Osaka City General Hospital) Yumiko Kagawa (Osaka Prefecture University) Ryoko Takayama (Kobe City College of Nursing) Hiroko Sumi (Kyoto University Hospital)
Session 4 Oncology Pharmacy ▶ 10:10 – 11:35...... 29 Chair persons: Midori Hirai, M.D., Ph.D. (Kobe University) Tomohiro Terada, Ph.D. (Shiga University of Medical Science Hospital) Masaaki Tanda (Kobe University) Yu Wen Wang, Ph.D. (National Taiwan University Hospital, Taiwan) Kanae Hanafusa (Osaka Medical College Hospital) Hyekyoung Eum, Ph.D. (Samsung Medical Center, Korea) Yuki Toda (Kyoto Pharmaceutical University)
Luncheon Seminar ▶ 11:50 – 12:50 ...... 34 Chair: Masahiro Hiraoka, M.D., Ph.D. (Professor and Chair, Department of Radiation Oncology, Image-applied Therapy, Kyoto University Graduate School of Medicine) Hirotsugu Kenmotsu, M.D. (Division of Thoracic Oncology, Shizuoka Cancer Center) Topics of NSCLC treatment and future direction Scott Bratman, M.D., Ph.D. (Princess Margaret Cancer Centre, Department of Radiation Oncology, University of Toronto, Canada) Circulating biomarkers for personalized treatment of lung and head and neck cancers
Session 5 Thoracic Oncology-2 ▶ 13:05 – 13:40...... 36 Chair persons: Takayasu Kurata, M.D. (Kansai Medical University) Naruo Yoshimura, M.D. (Osaka City University) Masato Terashima, Ph.D. (Kinki University) Helena Yu, M.D. (Memorial Sloan Kettering Cancer Center, USA)
Session 6 Gastrointestinal Oncology ▶ 13:40 – 14:50...... 38 Chair persons: Tatsuya Ioka, M.D. (Osaka Medical Center for Cancer and CVDs) Masakazu Yashiro, M.D. (Osaka City University) Hiroto Ueda, M.D. (Kinki University) Yoojoo Lim, M.D. (Seoul National University, Korea) Naoki Takegawa, M.D. (Kinki University) Chang-gon Kim, M.D. (Yonsei University, Korea)
Closing Ceremony ▶ 14:50 – 15:00 Closing Remark Tetsuya Mitsudomi, M.D., Ph.D. (Professor, Division of Thoracic Surgery, Department of Surgery, Kinki University Faculty of Medicine) Greeting from the Director of Investigators Training Section Upon the Opening of The 4th International Symposium of Training Plan for Oncology Professionals:
On behalf of “7-University Joint Project: Advanced Creative Plan for Cancer Education Base”, it is my great pleasure to announce you that the 4th International Symposium will be held on February 27- 28, 2016 in Osaka, Japan. Last year, we have held the 3rd International Symposium, which gathered 36 young investigators from all over the world, and had a great time of scientific discussion. The 4th International Symposium gathers 38 young investigators from 5 different countries including young Japanese doctors, who are currently being trained in 7-University Joint Project (or its graduates), investigators not only from 7-University but also Kyoto University, Kyoto Pharmaceutical University, Mie University, Osaka University, Osaka Medical College, Osaka City General Hospital, Shizuoka Cancer Center and some young yet outstanding investigators from Asian countries (Korea, Taiwan), Canada and the United States. We hope many of you will join this International Symposium and it will enrich your knowledge base and serve your advancement in the field of cancer treatment. We cordially welcome you to this 4th International Symposium of Training Plan for Oncology Professionals.
Kazuhiko Nakagawa, M.D., PhD. Professor and Chair, Department of Medical Oncology, Kinki University Faculty of Medicine
4 Messages from the Executive Secretariats of The 4th International Symposium of Training Plan for Oncology Professionals:
It is a great pleasure to invite you to participate in the 4th International Symposium of Training Plan for Oncology Professionals, taking place in Osaka, Japan on February 27-28, 2016. The aim of this symposium is to promote the mutual interaction between the Japanese young investigators, including medical oncologists, hematologists, radiation oncologists, surgeons, various kind of medical staff and foreign oncology researchers. Young investigators from 5 countries including USA, Canada, Korea, Taiwan and Japan who are actively involved in basic and clinical oncology research will give us presentation regarding their major field of research. In an attempt to continue the great success from last year, we expanded the capacity of symposium in several ways. 1 ) Poster presentation session was also added in the program. 2 ) In keynote lecture and luncheon seminar, we will have well-known oncology professionals to give us a lecture. We look forward to welcoming you to an exciting and fruitful event in Osaka, known as "City of Food".
Best regards,
Toshio Shimizu, M.D., PhD. Tsutomu Iwasa, M.D., PhD. Takeshi Yoshida, M.D., PhD. Junko Tanizaki, M.D., PhD.
Executive Secretariats of The 4th International Symposium of Training Plan for Oncology Professionals Department of Medical Oncology, Kinki University Faculty of Medicine
Toshio Shimizu, M.D., PhD Takeshi Yoshida, M.D., PhD Tsutom Iwasa, M.D., PhD Junko Tanizaki, M.D., PhD
Assistant Professor (Lecturer) Assistant Professor (Lecturer) Assistant Professor (Lecturer) Assistant Professor Phase I Clinical Trials Program Department of Medical Department of Medical Department of Medical Department of Medical Oncology Oncology Oncology Oncology Kinki University Faculty of Kinki University Faculty of Kinki University Faculty of Kinki University Faculty of Medicine Medicine Medicine Medicine Osaka, Japan Osaka, Japan Osaka, Japan Osaka, Japan
5 Ltd.
, . Chair Co
Kazuto Nishio, M.D., Ph.D. Ph.D. M.D., Nishio, Kazuto Tomoya Kawaguchi, M.D., Ph.D. M.D., Kawaguchi, Tomoya Kinki University Faculty of Medicine of Faculty Kinki University Keynote Lecture Professor, Department of Genome Biology, Biology, Genome Department of Professor, Graduate School of Medicine, Osaka City University Osaka Medicine, of School Graduate Pharmaceutical
Associate Professor, Department of Respiratory Medicine, Medicine, Respiratory of Department Professor, Associate clinical studies of angiogenesis inhibitors angiogenesis of studies clinical Director, Genome Center, Life Science Research GenomeDirector, Institute, Kinki Center, University Research Resident, Foundation for Promotion of Cancer Research Research National Institute Cancer at Center Head, Section of Drug Resistance, National Research Cancer Institute Center Research Laboratory, National Hospital Cancer Translational Director, Center Medical Tokyo University Clinical Proteome Center, Invited Professor, DepartmentInvited Professor, of Medicine, Internal Kitasato University School of Medicine Expert Pharmaceuticals and Member, Medical Devices Agency Professor and Chairman, Department of Genome Kinki Biology, University School of Medicine GeneticsInvited Researcher, Division, National Research Cancer Institute Center Prefectural Kyoto MedicalInvited Professor, University Graduate Medical of Wakayama Degree University, M.D. Staff, Fourth Department of Medicine, Internal Medical Wakayama University Hospital Research Staff, Pharmacology Division, National Research Cancer Institute Center Degree,Ph.D. Medical Wakayama University Molecular correlative studies in randomized randomized in studies correlative Molecular Chugai
DAY 1 DAY 2014-present 2006-present 2006-present 2010-present 2003-present 2005-present 1996-2006 2000-2006 2002-present 1990-1992 1992-1996 1994 Professional History: Kazuto Nishio 1986 1988-1990 6
Keynote Lecture DAY 1
The 4th International Symposium of Training Plan for Oncology Professionals February 27 (Sat), 2016 Yamato-no-Ma
Oral Session
Session 1 Radiation Oncology 12:40–14:00 Session 2 Oncology Nursing 14:05–15:00 Session 3 Thoracic Oncology-１ 15:00–15:50
Poster Session-1
Poster Viewing 15:50–16:20
Poster-1 Radiation Oncology 16:20–17:30
7
, , - - - - ) 1 1 , Hitoshi Tatebe 1 , Yasumasa Nishimura 1 , Kohei Fukuda 2 (Kobe University) , Shuichi Kanamori 1 , Kenta Sakaguchi 1 Abstract M.D Kinki University Faculty of Medicine M.D Kinki University of Medicine Kinki University Faculty Medicine University Hospital Faculty of Junior Resident, Kinki Kinki University Senior Resident, Department of Radiation Oncology, Faculty of Medicine , Kiyoshi Nakamatsu 1 Princess Margaret Cancer Centre Research Institute, University of Toronto, Canada Toronto, University of Institute, Research Centre Cancer Margaret Princess , Kazuki Ishikawa Scott Bratman, M.D., Ph.D. Ph.D. M.D., Bratman, Scott Ryohei Sasaki, M.D., Ph.D. Ph.D. M.D., Sasaki, Ryohei 2 2014 2006-2012 Research and professional experience 2012-2014 2014- Education 】 , Masaki Yokokawa 1 , Kohei Hanaoka 1 3 ( Radiation OncologyRadiation persons, Chair
】 】 】 Myocardial uptake on FDG-PET/CT after radiotherapy for esophageal cancer esophageal for after radiotherapy FDG-PET/CT on uptake Myocardial １ Session Conclusion Results Materials and Methods Purpose Masahiro Inada, M.D. Inada, Masahiro Central department of Radiology, Kinki University Faculty of Medicine Central department of Radiology, Kinki University Faculty of Medicine Institute of Advanced Clinical Medicine, Department of Radiation Oncology, Kinki University Faculty of Medicine, 377-2, Ohno-higashi, Osaka-Saya Our results suggested that focal uptake in myocardium after RT may reflect late myocardium damage caused by RT. Addition of the QPS analysis to MIP images may improve detailed analyses on focal uptake in the myocardium. nificantly associated with maximum dose in the left ventricle and V50Gy of the whole heart. In QPS analysis, 46 of 66 (70%) diffuse pattern in MIP showed focal uptake. cal pattern in MIP. cal pattern in MIP. Focal pattern tended to appear 180 days after start of RT especially in Mt or Lt patients. Focal pattern is sig included. In total, 287 PET images of the 98 patients were evaluated using maximum intensity projection (MIP) and Quantitative Perfusion SPECT (QPS). Myocardial uptake were visually classified in no, diffuse, or fo spectively. Between 2005 – 2012, FDG-PET/CT studies performed after RT for 98 patients with esophageal cancer were Myocardial uptake on FDG-PET/CT after radiation therapy (RT) for esophageal cancer were evaluated retro ma city, Osaka 589-8511, Japan Osaka 589-8511, ma city, 2 3 1 Masahiro Inada Izumi Tachibana Makoto Hosono 【 【 【 【 8
Session１ practice suchasradiotherapy andinterventionalradiology. clinical in tool useful be to expected is paper metal-functional The edge. k-absorption using cerium and also We tributions flexibly TFP-grid The collimator. cerrobend-grid with distributions dose d was which collimator cerrobend-grid the with compared were collimator TFP-grid the with axis off-center use be could TFP the investigated We tumors. superficial bulky for valid be to expected has therapy grid electron The TFP four and TFP single a using attained was 40% approximately of reduction dose A method. Carlo Monte and from emitted -ray γ by dose medical staff,families,andcaregiversshouldbeaslow aspossible.TheTFPwasusedtoreducetheexposure ( iodine-125 When a simulationofTFPbyMonteCarlomethod.Inthisstudy, wechallengedtoapplytheTFPinclinicalpractice. enough shieldingabilityinwiderangeofenergyforradiation validated We materials. other onto stick and fold, cut, to easy are they that features paper and lead-free, is ability.TFP shielding radiation with paper novel a is which powder, tungsten contains (TFP) paper Tungsten-functional flexible. not was it and environment and body human been has lead The 2 Osaka-Sayama City, Osaka589-8511,Japan 1 Mikoto Tamura Department ofRadiationOncology, KinkiUniversityFacultyofMedicine Department of Medical of Department e Session iscribed １ s hadequivalentshieldingeffecttocommercialleadunderwear. MikotoTamura tried in previous report by report previous in
to develop weight saving of the metal-functional paper besides tungsten such as tin, barium, tin, as such tungsten besides paper metal-functional the of saving weight develop to its radiation shielding ability for ability shielding radiation its Application of the tungsten-functional in clinical paper practice 1
( Chair persons, RadiationOncology , HajimeMonzen and canbe 125 wid I) seeds brachytherapy is prescribed to treat prostate cancer, the radiation exposure radiation the cancer, prostate treat to prescribed is brachytherapy seeds I) e ly Physics used for radiation shielding in clinical practice. However, the lead has toxicity for toxicity has lead the However, practice. clinical in shielding radiation for used usedintheelectrongridtherapy 125 , Kinki University Kinki , Education 2013-Present experience professional and Research 2015-Present 2011-2013 2007-2011 I. We investigated the radiation protection ability of TFP by measurements by TFP of ability protection radiation the investigated We I. 1 using ,
Makoto Hirata Ryohei Sasaki, M.D., Ph.D. Scott Bratman, M.D., Ph.D. Princess Margaret Cancer Centre Research Institute, of University Toronto, Canada Monte Carlo method. The TFP-grid collimator could reproduce the reproduce could collimator TFP-grid The method. Carlo Monte
the electron grid therapy. The dose distributions of depth and depth of distributions dose The therapy. grid electron the Japan Medical Sciences,Osaka,Japan Nagoya UniversityGraduateSchoolofMedicine,Aichi,Japan of HealthSciences,Aichi,Japan Clinical Radiology Service Division, Kinki University Hospital, Osaka, Hospital, University Kinki Division, Service Radiology Clinical of School Graduate University Kinki Physics, Medical of Department Sciences, Laboratory Medical and Radiological of Department School University Nagoya Technology, Radiological of Department 1 Graduate School of Medical Sciences, Medical of School Graduate Abstract , KazukiKubo in previousstudy
instead 1 , andYasumasa Nishimura
collimator could deliver excellent dose dis dose excellent deliver could collimator
of (Kobe University) (Kobe cerrobend-grid collimator . Furthermore,wesucceeded it has the advantages of advantages the has 377-2, Ohno-higashi, 377-2, 2 that the TFP had TFP the .
to ) -
9
Session１ ) neoadjuvant concurrent strategy; (Kobe University) through multidisciplinary approach outcomes
treatment Abstract MD at Sungkyunkwan University, School of Medicine School University, MD at Sungkyunkwan School of Medicine Graduate University, MMS at Sungkyunwan Rotating Samsung at Intern Medical Center Resident, Department of Radiation Oncology, Samsung Medical Clinical fellow, Department of Radiation Oncology, Samsung Center Medical Center
Samsung Medical Center, Sungkyunkwan University School of Medicine, Sungkyunkwan University Samsung Medical Center, Princess Margaret Cancer Centre Research Institute, University of Toronto, Canada Toronto, University of Institute, Research Centre Cancer Margaret Princess Scott Bratman, M.D., Ph.D. Ph.D. M.D., Bratman, Scott Ryohei Sasaki, M.D., Ph.D. Ph.D. M.D., Sasaki, Ryohei 1998-2004 2006-2007 Training 2004-2005 2005-2009 2012-2014 Education evaluation. Postoperative CCRT demonstrated better locoregional control than Oncology, Oncology, Yong Chan Ahn, Hyebin Lee, Hyojung Park, Dongryul Oh, Hongryull Pyo Chan Ahn, Hyebin Lee, Hyojung Park, Dongryul Oh, Hongryull Yong
( Radiation OncologyRadiation persons, Chair
preoperative Radiation Role of radiotherapy in patients with stage IIIA/B non-small cell lung cancer lung cell non-small IIIA/B stage with patients in radiotherapy of Role １ Session Jae Myung Noh, M.D. Noh, Myung Jae Radiotherapy contributes to the improvement of for patients with stage IIIA/B NSCLC. modulated radiation therapy (IMRT) enables to deliver high radiation dose to the target while sparing normal tissue safely. The 2-year PFS and OS following definitive CCRT with either 3D-CRT or IMRT were 38.7% and 75.2%, respectively. different (5-year rates, 77.3% vs. 79.3%; p=0.650). N3-IIIB disease is often difficult to be safely covered by 3-dimensional conformal radiation therapy (3D-CRT). Supraclavicular LN metastasis from the lower lobe primary tumor is a typical problematic example. Intensity- not evident on postoperative chemotherapy alone (5-year rates, 80.9% vs. 62.9%; p=0.003), while OS was not significantly For patients who were poor candidates for surgical resection, definitive CCRT (66 Gy in 33 fractions) has been recommended. After median follow-up of 18.8 months, the 2-year PFS and OS rates were 45.9% and 50.1%, respectively. Some patients have pathologic N2 disease after primary surgical resection, which was For patients with N2-IIIA NSCLC, our institution has adopted trimodality chemoradiotherapy (CCRT) followed by surgical resection. With median follow-up of 35.3 months, the 5-year progression free survival (PFS) and overall survival (OS) rates were 26.9% and 43.3%, respectively. Stage IIIA/B non-small cell lung cancer (NSCLC) involves quite heterogeneous disease extent due to the diversity of the location of primary tumor and metastatic lymph nodes (LNs). Therefore, a multimodality approach is generally recommended. 81, Irwon-ro, Gangnam-gu, Seoul 06351, Republic of Korea 81, Irwon-ro, Gangnam-gu, Seoul 06351, Jae Myung Noh, Department of 10
Session１ the reducedcoenzymeQ10asbasisofdrug. use to attempt the that believe we finally and drug target molecular a as acts that drug a produced be can it that believe we occurred, has damage radiation the when metabolism the of mechanism the clarify We the livingbodywithlatesttechnology. in present metabolites all analyzed comprehensively be can analysis study the in used be to Metabolome dose, suchascauseintestinaldeath. high of radiation with ed irradiat is it when tract intestinal the of variation metabolic the examined we First, small intestineinvivo. the of radioprotector potent and novel was Q10 Coenzyme of form reduced the that found had already We We thoughtthataradioprotectiondrugforradiationtherapythesmallintestinewasnecessary radiation damagehasnotbeenproposed. the selectively avoid to method effective however, organ, radiosensitive highly a as known is intestine Small 1 Saki Osuga Division ofRadiationOncology, KobeUniversityGraduateSchoolofMedicine, Session １ Saki Osuga,Saki M.D. Discovery of novel Index of radiation gastrointestinal disorders via metabolomics 1 , SachikoInubushi
( Chair persons, RadiationOncology 1 , Yasuo Ejima Education 2015-present 2014-2015 2010-2014 Ryohei Sasaki, M.D., Ph.D. Scott Bratman, M.D., Ph.D. Princess Margaret Cancer Centre Research Institute, of University Toronto, Canada
1 , HiroakiAkasaka Engineering, DoshishaUniversity(KyotoJapan) A doctor'scourseofKobeUniversityGraduateSchool ofMedicine A master'scourseofKobeUniversityGraduateSchool of Medicine Biomedical of Department Science, Medical and Life of Faculty Abstract 1 , DaisukeMiyawaki (Kobe University) (Kobe
Kobe, Hyogo,Japan 1 , RyoheiSasaki 1 . ) 11
Session１ ------) , Ya 4 , Masao Tanooka 1 .
1 (Kobe University) , Kazuhiro Kitajima 3 , and Shozo Hirota 1 Pathology Hyogo College of Medicine, 1-1, Mukoga 5 Abstract , Toshiyuki Shikata 1 Resident, Kobe University Hospital, Hyogo, Japan Resident, Kobe University Resident, Department of Internal Medicine, Kinki Central Hospital of Clinical Hyogo research College associate, Department of Radiology, Visiting Scholar, Department of Radiation Oncology, Stanford Assistant Professor, Department of Radiology, Hyogo College of the Mutual Aid Association of Public School Teachers, Hyogo, Japan of Public School Teachers, the Mutual Aid Association Japan of Medicine, Hyogo, California, USA University School of Medicine, Stanford, Medicine, Hyogo, Japan
Princess Margaret Cancer Centre Research Institute, University of Toronto, Canada Toronto, University of Institute, Research Centre Cancer Margaret Princess Scott Bratman, M.D., Ph.D. Ph.D. M.D., Bratman, Scott Ryohei Sasaki, M.D., Ph.D. Ph.D. M.D., Sasaki, Ryohei , Norihiko Kamikonya 2005 M.D., Kochi Medicine School 2005 M.D., Kochi Medicine of Medicine 2012 Ph.D. Hyogo College Employment and Training Professional 2005-2007 2007-2008 2008-2011 2012-2013 present 2011- Education 5 , Soichi Odawara Thoracic Surgery, and 2 2 Radiology, Radiology, 1 ( Radiation OncologyRadiation persons, Chair
, Tohru Tsujimura , Tohru 1 Pravastatin Reduces Radiation-Induced Damage to Normal Tissues Normal to Damage Radiation-Induced Reduces Pravastatin , Seiji Matsumoto 1 １１ SessionSession Department of Radiological Technology, The Hospital of Hyogo College of Medicine, 1-1, Mukogawa-cho, Department of Pharmacy, Hyogo College of Medicine Sasayama Medical Center, Kurooka 5, Sasayama, Hy Hiroshi Doi, M.D.,Ph.D. Doi, Hiroshi ble-strand breaks. Pravastatin may increase the therapeutic index of radiotherapy tion. Pravastatin had radioprotective effects on the intestine and lung and reduced radiation-induced DNA dou of the intestine (P < 0.0001) and tended to show reduced apoptosis in the lung (P = 0.060). Pravastatin re duced the intestinal expression of gamma-H2AX and ataxia telangiectasia mutated (ATM) after irradiation. No apparent pravastatin-related differences were observed in the response of xenograft tumors to irradia model. Pravastatin increased the number of viable intestinal crypts and this effect was statistically significant in the ileum (P < 0.0001). The pravastatin group showed significantly lower apoptotic indices in all examined parts cell survival and the incidence of apoptosis in the intestine and lung were measured post-irradiation. The effect of pravastatin on intestinal DNA damage was determined by immunohistochemistry. Finally, we ex amined the effects of pravastatin on tumor response to radiotherapy in a mouse mesothelioma xenograft and and the pravastatin group received pravastatin prior to ionizing radiation. Pravastatin was administered orally at 30 mg/kg/body weight in drinking water 24 h and 4 h before irradiation. Intestinal crypt epithelial therapeutic applicability in a broad range of inflammatory conditions. The purpose of the present study was animal model. to assess the radioprotective effects of pravastatin in an experimental Mice were divided into two groups: the control group received ionizing radiation with no prior medication Nishinomiya City, Hyogo, 663-8501, Japan Nishinomiya City, Pravastatin is an inhibitor of 3-hydroxy-3-methyl-glutaryl-CoA reductase that has been reported to have a ogo, 669-2321, Japan 4 Departments of 663-8501, Japan Hyogo, wa-cho, Nishinomiya City, 3 Hiroshi Doi suhiro Takada 12
Session１ education aboutthepainmonitoringguidelineforsystematic andeffectivepainmanagement. intensive with nurses oncology the provide to and program monitoring pain the develop to necessary is it Therefore, nurse. oncology a by assessment pain regular the through decreased is patient cancer the behavior. assessment pain and management, pain toward attitude and about knowledge the of level the improving for significant statistically was nurses oncology the for program pharmacologic and attitudes attitudes, and knowledge between indicated was correlation positive management, pain cancer Results: is usedbyHYJho,YKim,DHJYChoi,EJNamet al which tool research complemented and modified a with measured were management pain cancer garding and attitudes, knowledge, The Record. Medical Electronic the analyzing practices, clinical the at implementation and group focus workshop, lectures, group several including od meth teaching various with it constructed and literature, the on based developed was program monitoring nurses. oncology in pain cancer of ability assessment and attitude knowledge, Purpose: Hospital, Center Care 1 Hyunjin Jang Nursing department, Yonse department, Nursing Session 2 MSN, RN, OCN Hyunjin Jang,
In accordance with the correlation among knowledge, attitudes and assessment regarding the regarding assessment and attitudes knowledge, among correlation the with accordance In Yonsei This study was purposed to identify the effect of pain monitoring program for improving the improving for program monitoring pain of effect the identify to purposed was study This , 1 3 , Yo Yons Chair persons, Nursing Oncology Cancer Center, Seoul,Korea Evaluation of pain monitoring program for oncology nurses un ei assessment jung Hu
Cancer Center, Cancer 2 i , M University Health System, Severance Hospital, Cancer Center, Cancer Hospital, Severance System, Health University , knowledge and pharmacologic intervention (p=0.05). intervention pharmacologic and knowledge , ee Education Mar, 2003-Mar, 2009 experience professional and Research 2008-2010 2006-2008 1999-2002 June, 2015-Present Nov, 2014-2015 April, 2009-2013 June, 2008 young Cho Shizue Suzuki, Ph.D., RN Harue Arao, Ph.D., RN Department of Medical Oncology, Medical of Department
. 1 Master ofScienceDegreeinOncologyNursing Yonsei UniversityNursingofGraduateSchool,Seoul, Korea Bachelor ofScienceDegreeinNursing Yonsei UniversityCollegeofNursing,Seoul,Korea Daegu HealthCollegeofNursing,Daegu,Korea
, H
ye
Abstract J in center¥ University HealthSystem Severance Hospital Severance Hospital University HealthSystem On a surgical oncology unit at Severance Hopital, Yonsei Hopital, Severance at unit oncology surgical a On Nurse(R.N) Education nurse, Inpatient nursing team. Yonsei cancer Yonsei team. nursing Inpatient nurse, Education at Clinic Cancer Pancreatocobiliary Outpatient in On Nurse(R.N) /PancreatocobiliaryCancerCoordinator at Course Nurse Continence Ostomy Wound , Instructor Nurse(R.N) / Palliative Care Center Coordinator, Yonsei Coordinator, Center Care Palliative / Nurse(R.N) . Choi
(2014) 3 .
(Osaka University) (Osaka
(Kobe City College(Kobe of Nursing) City Yonsei Medical college, Medical Yonsei assessment Conclusion: Methods: of oncology nurses re nurses oncology of
The pain intensity of intensity pain The The pain monitoring pain The In this study pain study this In 2 Acute Palliative Acute
Severance - - 13
Session ２
- 5) ±
– p < 11.4
± 1.4;
assessing HT 34.5 ± particularly in significantly
and returned 1.7 CT+ HT 56.6 ( vs.
-item scale, which changes 28 18.4
± vs. CT+HT
who began receiving HT Higher scores (range, 0 Cancer Education and Re
. 2 1.3 , difficulty managing memory, : ± HT 26.7 women ( 1.4 factors approved this study. (Kobe City Nursing) of (Kobe College (HT
evaluated using a as (Osaka University) (Osaka three w can provide useful information , 1-7, Yamadaoka, Suita City, Osaka 565-0871, s during treatment. We compared self-reported ypes of medications for HT were not . The HT group was significantly older significantly different change ethics committee receiving hormonal therapy (HT) with and without prior Abstract 1 Although t Osaka University Graduate School of Medicine, Division of Health Master of Science in Nursing, Osaka University Graduate School of Bachelor of Science in Nursing, Osaka University Division of Health Sciences, Advanced Research Course of Cancer Nursing Sciences, Advanced Health Sciences Medicine, Division of Sciences ional ). : A comparison between breast cancer patients patients between cancer breast : A comparison
women Harue Arao 5, t-test
HT with prior CT may increase the risk of cognitive he institut
Harue Arao, Ph.D., RN Ph.D., Arao, Harue Shizue Suzuki, Ph.D., RN Ph.D., Suzuki, Shizue T changes ). 0.0 . and
completed an anonymous, self-administered questionnaire 2013-present 2013 2011 Education < 2 cceptable reliability and validity were obtained The CT+HT group reported higher scores for all factors. For the third factor, s between
the length of HT was . A p
) , ; The frequency of cognitive changes change , t-test mail. in order. Participants 10.7 years by
s. , Eiko Masutani 1 ±
Oncology Nursing persons, Chair third , 510 (58.2%) responded. We analyzed the data from 347
(HT 220 women, CT+HT 127 women) receiving hormonal therapy with and without prior chemotherapy prior without and with therapy hormonal receiving p < 0.001 ; change MSN, RN MSN, women HT 53.8 Self-reported cognitive Self-reported cognitive two-way analysis of variance 2
Sena Yamamoto, Yamamoto, Sena CT+ 1, Session Division of Health Sciences, Osaka University Graduate School of Medicine he questionnaire cognitive they had a significantly higher score regardless of the length of HT 0.0 in maintaining concentration and attention. Treatment history vs. different between the groups 19.6 months represent more frequent changes Of 876 within 5 years difficulty performing several parallel functions, and difficulty maintaining concentration and attention, from the first to the chemotherapy (CT). t we developed based on previous studies. These items yielded Patients with breast cancer are at risk of cognitive frequency of cognitive search Center, Osaka University Graduate School of Medicine Japan Sena Yamamoto 1 14
Session ２ CRCs isveryimportanttoimprovethequalityofclinical trials. of quality The year. every training refresher a complete to have CRCs apprenticeship. and lectures includes and program, 18-months is It CRCs. for program educational own their has (CTC) Center Trials Clinical SNUH They have10regularnursesand50CRCs. laboratory. and pharmacy separate with couches 20 and trials, I phase for beds monitored fully 10 has unit This trials. of efficiency and quality the improve to Unit Trials Clinical Oncology independent operates SNUH professional ClinicalResearchCoordinators(CRC). and investigators enthusiastic without possible be not would success This companies. foreign from pounds com the with done were 22 and 2014, in studies I phase 28 conducted They trials. international are those of 3/4 about and year, every trials clinical 60 approximately initiate They trials. of quality and quantity both in team active most the is team Oncology Medical SNUH, In Seoul. in trials clinical for hospital top the is SNUH 1 maintains that trials clinical international of Mecca the became Seoul success. quantitative and qualitative the both achieved SNUH progress, this During trials. clinical international the of site core the of one become to (SNUH) Hospital University National Seoul made eventually which rapidly increased studies multi-national era, globalization the to reaches development drug for trials clinical the As Clinical Trials Center, Seoul,RepublicofKOREA 1 Mie SoonIn Clinical ResearchManager, SeoulNationalUniversityHospital Session Mie Soon In, RN 2 1 Chair persons, Nursing Oncology Role of the Clinical Research Coordinator SNUH at Education 2008.12.6 2008.11.1 -29 2014.10 .14 2007.8 Training Seoul NationalUniversityCollegeofNursing,Seoul,Korea:BSN Shizue Suzuki, Ph.D., RN Harue Arao, Ph.D., RN The ProfessionalEducationforClinicalResearchCoordinators. The AdvancedCourseforClinicalResearchCoordinators. Participate inSNUHGCPTraining :e-Learningprogram Participate inSNUHCTCCRCFellowshipTraining Program Abstract (Osaka University)
(Kobe City College(Kobe of Nursing) City st place for few years in a row, and row, a in years few for place - 15
Session ２
, ------3 , Yeun-Chung Chang 2
Department of Medical Imaging, 3 , Jin-Yuan Shih 2 (Hyogo College of Medicine) of College (Hyogo
and (Kobe University) (Kobe , Chao-Chi Ho 3 Staff Physician, National Taiwan University Hospital Hsin-Chu Hospital University Taiwan Staff Physician, National M.D. School of Medicine, Medical College, National Cheng Kung University, Taiwan Aug. 2006-Jun. 2012 Resident and University Hospital National Taiwan Oncology Fellowship,
Abstract 1 , Yeefan Lee 2 Toru Mukohara, M.D. Mukohara, Toru Kozo Kuribayashi, M.D. Kuribayashi, Kozo patients pretreated with EGFR-TKIs with pretreated patients Past and Current positions Jul. 2012-Jun. 2014 Branch Jul. 2014- Sep 1998-June 2005 1998-June Sep Education Department of Internal Medicine 2 , , Shu-Yung Lin 1 ncology O
Thoracic Oncology-1 persons, Chair , and James Chih-Hsin Yang 2 , Chia-Chi Lin 1 Outcomes of research biopsies in clinical trials of EGFR mutation- positive NSCLC NSCLC positive mutation- EGFR of trials clinical in biopsies research of Outcomes 3 Bin-Chi Liao, M.D. Bin-Chi Liao, Session Department of
tient required chest tube placement for pneumothorax, and two patients underwent endotracheal intuba tion because of RBs related bleeding. RBs in this population were safe, but potential risk of RBs related com plications should be discussed with the clinical trial participants. trasound-guided RBs (32.0%) and bronchoscopy (16.0%). The most common sites of RBs were lung (69.6%), pleura (8.8%), and liver (6.1%). Pathologic exams disclosed malignant cells in most specimens of RBs (72.9%). Complications of RBs included pneumothorax (10.5%), bleeding (6.1%), and infection (1.1%). Only one pa tients had been treated with gefitinib, erlotinib, and afatinib, respectively. Sixteen patients (11.4%) under went multiple RBs for a clinical trial to obtain adequate tissue samples. A total of 181 RBs were performed, and computed tomography-guided RBs were the most frequently used modality (50.8%), followed by ul patients (97.9%) had adenocarcinoma histology, and 73 (52.1%) and 59 (42.1%) patients had deletions in exon 19 and exon 21 L858R mutation, respectively. Before RBs, 108 (77.1%), 83 (59.3%), and 36 (25.7%) pa kinase inhibitors (TKIs). We searched the medical records of NSCLC patients participated in lung cancer clin ical trials from 2012 to 2014 in National Taiwan University Hospital. We identified 140 EGFR mutation-posi tive patients who were pretreated with EGFR-TKI and underwent mandatory RBs for the clinical trials. Most Research biopsies (RBs) are crucial in developing novel molecular targeted agents. The safety and success rate of RBs have not been studied in EGFR mutation-positive NSCLC patients pretreated with EGFR tyrosine 1 Taiwan Taipei, University Hospital, 7, Chung-Shan South Road, National Taiwan Chong-Jen Yu Bin-Chi Liao 16
Session ３ these tumorscanbebesttreatedwithafatiniborneratinib. with patients and practice clinical in overlooked be not should mutations 18 exon harboring cancers lung Conclusion: data. clinical as well as experiments vitro in on based generation-TKIs third and first to than neratinib, and afatinib especially generation-TKIs, second to sensitivities higher have to appeared mutations these harboring cers can Lung COSMIC. and Center Cancer Aichi at databases the to according mutations EGFR all of 3-4% in ent Results: ties ofretrovirally-transfectedBa/F3cellstovariousEGFRTKIs,includingthreegenerationsTKIs. Methods: However, littleisknownaboutmutationsinexon18. spond toEGFRtyrosinekinaseinhibitors(TKIs). Introduction: 464-8681, Japan, Center,Cancer Nagoya, Chikusa-ku, Aichi Diagnostics, Kanokoden, Molecular 1-1 and Pathology of partment Japan, 589-8511, Osaka City, 1 Nishio Shimoji Masaki Kobayashi Yoshihisa
YoshihisaKobayashi, EGFR 18 exon mutations in lung cancer: molecular predictors of augmented sensitivity Department of Department Session 3 2 , andTetsuya Mitsudomi1 Exon 18 mutations including G719X, E709X, and exon 18 deletion 18 exon and E709X, G719X, including mutations 18 Exon This study comprehensively focused on exon 18 mutations and investigated the in vitro sensitivi vitro in the investigated and mutations 18 exon on focused comprehensively study This to afatinib or neratinib as compared or third-generation with first- TKIs M.D. Although the currently available in vitro diagnostic kits do not detect all exon 18 mutations, 18 exon all detect not do kits diagnostic vitro in available currently the Although Lung cancers harboring common EGFR mutations, exon 19 deletions and L858R mutation, re mutation, L858R and deletions 19 exon mutations, EGFR common harboring cancers Lung 1 Chair persons, Oncology-1 Thoracic , Katsuaki Sato Katsuaki , Thoracic Surgery Thoracic 4 DepartmentofThoracicOncology, AichiCancerCenter 1 Yosuke Togashi Yosuke 2 1 Department of Genome Biology, Kinki University Faculty of Medicine, of Faculty University Kinki Biology, Genome of Department , Kenichi Suda Kenichi , Education 2014-present 2012-2014 2010-2012 2008-2010 experience professional and Research 2014-present 2002-2008 1
, Kinki University Faculty of Medicine, 377-2, Ohno-higashi, Osaka-Sayama Ohno-higashi, 377-2, Medicine, of Faculty University Kinki , Kozo Kuribayashi, M.D. Toru Mukohara, M.D. 2 , Yasushi Yatabe Yasushi ,
1 Faculty ofMedicine Center Assistant Professor, Department of Thoracic Surgery, Kinki University Cancer Aichi Surgery, Thoracic of Department resident, Senior Resident, DepartmentofThoracicSurgery, AichiCancer Center Resident, IizukaHospital Graduate SchoolofMedicalSciences,KinkiUniversity Mie UniversityFacultyofMedicine , Kenji Tomizawa Kenji , Abstract 3 , Hiroshi Mizuuchi Hiroshi , 1 (Kobe University) , Toshiki Takemoto Toshiki ,
(Hyogo College of Medicine) （ 1 , Park Jangchul Park , delE709_T710insD 1 , Toyoaki Hida Toyoaki , 4 , Chiaki Kondo Chiaki , ） were pres were
4 , Kazuto , 3 De 3 - - - - - , 17
Session ３
- - - rd mutation EGFR (Hyogo College of Medicine) of College (Hyogo
(Kobe University)
1 generation EGFR-TKIs (WZ4002 and ASP8273). Dasatinib Abstract rd Osaka City University school of Medicine , Osaka, Japan school of Medicine , Osaka, Osaka City University Graduate school of Medical Science, Kinki University Faculty of hospital, Osaka, Japan Bell-land general Resident doctor, Research associate, Department of Medical Oncology, Kinki Medicine, Osaka, Japan Medicine, Osaka, Japan University Faculty of
, and Kazuhiko Nakagawa generation EGFR-TKI in lung cancer cell lines with T790M mutation T790M with lines cell cancer lung in EGFR-TKI generation 1 Toru Mukohara, M.D. Mukohara, Toru Kozo Kuribayashi, M.D. Kuribayashi, Kozo rd 2006-2012 2014- Research and professional experience 2012-2014 2014- Education , Takeshi Yoshida , Takeshi 1
Thoracic Oncology-1 persons, Chair M.D. ~ In order to optimize the treatment for EGFR T790M-positive NSCLC patients ~ patients NSCLC T790M-positive EGFR for treatment the optimize to order ~ In 3 Satomi Watanabe, Satomi Watanabe, Session Department of Medical Oncology, Kinki University Faculty of Medicine, 377-2, Ohno-higashi, Osaka-Sayama Kinki University Department of Medical Oncology, vitro respectively. vitro We respectively. are now preparing for in vivo experiments, which would be a rationale for future clini cal study. tinib in gefitinib-resistant NSCLC xenografts with T790M. Given these results, we subsequently conducted combination experiments using dasatinib with 3 combined with WZ4002 or ASP8273 effectively inhibited cell proliferation and increased apoptotic cells in dasatinib plus irreversible EGFR-TKI afatinib abolished Src phosphorylation and suppressed downstream phosphorylated Akt and Erk in T790M positive NSCLC cells. Afatinib combined with dasatinib inhibited cell growth and increased apoptotic cells in these cell lines. Dasatinib also enhanced antitumor effects of afa (exon (exon 19) and paired PC9GR (gefitinib-resistant) cells with T790M, using immunoaffinity purification of ty rosine-phosphorylated peptides and mass spectrometry-based identification/quantification. As a result, we identified a Src family kinase (SFK) as one of co-driver signals in the presence of T790M. The SFK inhibitor We hypothesized additional resistance mechanisms cooperate with T790M could be identified by profiling tyrosine phosphorylation in T790M positive NSCLC cells. We profiled PC9 cells with sensitive with acquired resistance to EGFR-TKIs have the T790M secondary EGFR mutation. T790M-selective (3 generation) EGFR-TKIs are thought to be one strategy to overcome T790M-related resistance. However, NSCLCs. there still be a need to optimize the treatment against T790M positive EGFR mutations are detected approximately 30-40 % of non-small cell lung cancers (NSCLCs) in Asian patients. NSCLC patients with EGFR mutations are initially sensitive to treatment with EGFR-tyrosine kinase inhibitors (EGFR-TKIs), but they eventually acquire resistance in 1-2 years. Nearly 50 % of NSCLC patients City, Osaka 589-8511, Japan Osaka 589-8511, City, Satomi Watanabe 1 Dasatinib in combination with 3 with combination in Dasatinib 18
Session ３ Hajime Monzen, M.D., Ph.D. Keita Yoshizaki Keita Yuhei Koike Yuhei quency still remains controversial. The aim of this study is to quantify the dosimetric impact of intra-fractional of impact dosimetric the quantify to is study this of aim The controversial. remains still quency fre imaging optimal the and revealed be can’t images consecutive two between motions organ However, imaging. X-ray orthogonal the by motions intra-fractional manage can CyberKnife using SBRT cancer. tate Background: 3 2 aoka, Suita,Osaka565-0871,Japan 1 Masahiko Koizumi Koike Yuhei Abstract 2014-Present 2010-2014 Education robotic radiosurgery hypofractionated for irradiation during motion prostate intra-fractional of impact Dosimetric the PARPimayhavepotentialtherapeuticbenefitswithhypofractionatedradiotherapy that suggesting lines, cell cancer colorectal on HDI to effects radiosensitizing significant showed PARPi The repair. PJ34andolaparibdisplayeddifferentialeffectsonRad51versus53BP1fociformation. DSB DNA of kinetics the on impacted PARPi the revealed assays Immunofluorescence HDI. and LDI both using delay regrowth a showed Olaparib alone. radiation with compared LDI following found was difference no but and HDI, with spheroids LDI of delay regrowth both substantial a showed PJ34 to Similarly, assays. colony-forming the sensitized on HDI olaparib while LDI, to not but HDI to cells the sensitized PJ34 that observed We was performedtomeasurekineticsofDNAdouble-strandbreaks(DSB)repairwithorwithoutthePARPi. formation foci γH2AX,53BP1 of and imaging Rad51, immunofluorescent The PARPi. the without or with HDI and LDI following conducted were spheroids cellular three-dimentional using assays regrowth Tumor cells. using colony-formingassaysatlow-doseirradiation(LDI)andhigh-dose(HDI)onHT29HCT116 olaparib) and (PJ34 PARPi including radiosensitizers potential 18 of effects radiosensitizing evaluated We as worked be can radiosensitizers incombinationwithhigh-doseirradiationoncolorectalcancercelllines. they not or whether (PARPi) inhibitors PARP evaluate to is study this of aim The 565-0871 Osaka,Japan 2 1-7, Suita,565-0871Osaka,Japan 1 Kazuhiko Ogawa Yoshizaki Keita Abstract 2014-present 2010-2014 Education Lines Cell Cancer Colorectal in Irradiation High-dose with PARP of Inhibitors Effect Sensitizing The small. was motion intra-fractional of impact dosimetric the institution, our in motion prostate these Under motions. prostate intra-fractional of correction the without and with between parameters dose-volume most in 1.0%) (< difference no was There respectively. directions, superior-inferior in mm 2.06 ± -0.15 and left-right, in Result: pared withthoseintheoriginaldosesusingDVHtermsofCTV com were doses predicted The motion. organ intra-fractional with dose predicted the create to calculation dose the into incorporated and system CyberKnife the from exported were log-files FM fractions. five in Gy 35 Methods: prostate motionsthroughthedose-volumehistogram(DVH). Department ofRadiology, OsakaUniversityHospital Department ofRadiationOncology, OsakaUniversityGraduateSchoolofMedicine Department of Medical Physics and Engineering, Osaka University Graduate School of Medicine, Yamadaoka Medicine, of School Graduate University Osaka Engineering, and Physics Medical of Department Department of Medical Physics and Engineering, Osaka University Graduate School of Medicine, 1-7 Yamad 1-7 Medicine, of School Graduate University Osaka Engineering, and Physics Medical of Department Department of Radiation Oncology, Osaka University Graduate School of Medicine, Yamadaoka 2-2, Suita, 2-2, Yamadaoka Medicine, of School Graduate University Osaka Oncology, Radiation of Department The displacement of FMs in each beam was 0.79 ± 1.99 mm in anterior-posterior, -0.09 ± 0.81 mm 0.81 ± -0.09 anterior-posterior, in mm 1.99 ± 0.79 was beam each in FMs of displacement The Yoshihito Nomoto, M.D., Ph.D. Sixteen patients implanted three fiducial markers (FMs) were selected. The prescription dose was dose prescription The selected. were (FMs) markers fiducial three implanted patients Sixteen 1 , Iori Sumida Iori , Hypofractionated stereotactic body radiation therapy (SBRT) is an attractive strategy for pros for strategy attractive an is (SBRT) therapy radiation body stereotactic Hypofractionated
1 2 , Yuji Seo Yuji , Poster Session 1 Department of Medical Physics and Engineering, Osaka University Graduate School of School Graduate University Osaka Engineering, and Physics Medical of Department Departments of Medical Physics and Engineering, Osaka University Graduate School of School Graduate University Osaka Engineering, and Physics Medical of Departments Osaka UniversityDivisionofHealthSciences Division ofHealthScience,OsakaUniversity Medicine Medicine , MasahikoKoizumi 1
(Kinki University) (Kinki Radiation Oncology 2 , Hirokazu Mizuno Hirokazu , 2 , Kazumasa Minami Kazumasa , Chair persons Chair 1 Masahiko Koizumi, M.D., Ph.D. 2 , Hiroya Shiomi Hiroya , 1 , Keisuke Tamari Keisuke , (Mie University) 2 , Keita Kurosu Keita , , PTV, rectum,bladder, andurethra. 2 , Masaaki Takashina Masaaki , 2 , Seiichi Ota Seiichi , . 1 3 , Fumiaki Isohashi Fumiaki , , Kazuhiko Ogawa Kazuhiko , (Osaka University) (Osaka 2 2 - - - - , , 19
Poster Session 1 Poster Session 1 , ------2 . (Osaka University) , Hajime Sakuma 4 , Yoshihiro Komada 4 (Mie University)(Mie , Hidemi Toyoda 3 1 Masahiko Koizumi, M.D., Ph.D. Ph.D. M.D., Koizumi, Masahiko Chair persons , Ryohei Sasaki 1 , Toshio Matsubara 1 Patients who received MRI with DWI and ADC map at least twice during the IGABT Patients who received MRI with DWI and ADC Radiation Oncology Radiation (Kinki University)
We are going to evaluate relationship between changes of ADC values during IGABT and 1 M.D. kyorin University kyorin University (Tokyo, Japan) Resident, Aichi cancer center Medical staff, Southern TOHOKU Proton Therapy Center Medical staff, Mie university hospital M.D. Kobe University School of Medicine M.D. Kobe University School of Medicine Kobe University School Hospital Junior resident, Kobe Asahi Hospital Junior resident, Kobe University Awaji hospital Medical staff, Hyogo prefectural Hospital Medical staff, Osaka Police Medical staff, Kobe University Hospital , Noriko Ii Poster Session 1 Session Poster 1 , Kenji Yoshida , Kenji Yoshida Image guided adaptive brachytherapy (IGABT) has been widely accepted for cervical carcino 1 Yoshihito Nomoto, M.D., Ph.D. Ph.D. M.D., Nomoto, Yoshihito Department of Radiation Oncology, Mie University Hospital, 2-174, Tsu, Mie, 514-8507, Japan, Mie University Hospital, 2-174, Tsu, Department of Radiation Oncology, Mie, 514-8507, Japan Mie University Hospital, 2-174, Tsu, Department of Radiology, Mie, 514-8507, Japan Mie University Hospital, 2-174, Tsu, Department of Neurosurgery, Mie, 514-8507, Japan Department of pediatrics, Mie University Hospital, 2-174, Tsu, late adverse effect. Intensive chemotherapy followed by reduced dose and field irradiation resulted in preferable outcomes. Based on our results, further study will be required from the perspective of radiation dose and field, especially for patients classified as intermediate and poor prognosis group. Yoshihito Nomoto Yoshihito 1 2 3 4 The purpose of this study is to report the treatment outcomes of intensive chemotherapy reduced followed dose by and field irradiation for the treatment of intracranial germ cell tumors (GCTs). males 22 and 4 females) patients with intracranial GCTs (18 were treated at our facility between 1991 and 2012. The medium follow-up duration was 116 months, 10-year overall survival rate and progressive-free survival rate was 80.1% and 69.4%, respectively. Regarding late adverse effect, pituitary dysfunction (short stature, insufficiency of secondary sexual feature, hypothyroidism); 8 patients (36%), hearing impairment; 6 patients (27%), intelligence diminution; 6 patients (27%), convulsion/electroencephalogram abnormality; 5 patients (23%), treatment induced secondary neoplasm; 2 patients (9.1%), motility disorder; 2 patients (9.1%), azoospermia; 1 patient (4.5%) and treatment-related death (brain hemorrhage); 1 patient (4.5%) appeared. In addition, (23%) 5 patients needed intervention of a psychiatrist due to school refusal, anxiety disorder, eating and disorder self-injury behavior etc. In contrast, patients who received irradiation less than 30 Gy tended to have no FUTURE OUTLOOK: treatment response. If the results of our study can help the prediction of poor stage, response additional to IGABT CRT procedure at may an be early an alternative strategy for the dose escalation to cancer. local control in such a radioresistant cervical achieve better Long-term follow-up of intensivechemotherapy followed by reduced dose and field irradiation for intracranial germ cell tumors Education 2006 2000-2006 Research and professional experience 2007.4-2009.2 2009.2-2013.5 2013.6-present Abstract Akinori Takada Kobe City, Hyogo Prefecture, JAPAN, 650-0017, Main Phone No: +81-78-382-5111 Hyogo Prefecture, JAPAN, Kobe City, BACKGROUND: ma. While computed tomography (CT) is generally used for IGABT in Japan, MRI, which is superior in contrast resolution, also recently come to be used in practice. As a special distinction of histological MRI, character can images be that obtained such represent as Diffusion Weighted Images (DWI) and Apparent Diffusion Co efficient (ADC) map. Recently, several reports have reported that ADC is useful for the evaluation of response to chemoradiotherapy (CRT) for cervical cancer. However, there is no report investigating the relationship be tween the change of ADC value during IGABT period and local control in cervical cancer treatment. In our in stitution, we have applied MRI for the treatment planning for all the IGABT procedure from October 2014, and also have retrieved DWI and ADC map from January 2015. The purpose of this study is to investigate whether can predict the local controllability of cervical cancer the change of ADC value during IGABT period AND METHOD: MATERIALS period from October 2014 to September 2015 were included in the study. All the with patients same MRI were device examined (Philips Ingenia 3.0T), with same protocols. HRCTV and Organs at Risk (OARs) were de lineated with MR image and if needed, fused CT image. Dose prescription were first determined tional by point-A prescription, then optimized aiming dose more of than HRCTV, 7 Gy considering those conven of OARs. SD, skewness, and kurtosis are calculated, and changes in theseADC values are extracted, then mean, median, between those parameters and tumor control. values are assessed to investigate the relationship Assessment of Apparent Diffusion Coefficient during Image Guided Adaptive Brachytherapy for the Prediction of local controllability in Cervical Cancer Treatment Education 2008 2002-2008 Research and professional experience 2008 2009 2010-2011 2012-2013 2014- Abstract Ryo Nishikawa Kobe University Graduate School of Medicine Division of Radiation Oncology, 7-5-2 Kusunoki-cho, Chuo-ku, M.D. M.D. Ryo Nishikawa, Akinori Takada, Takada, Akinori Hajime Monzen, M.D., Ph.D. M.D., Monzen, Hajime 20
Poster Session 1 Poster Session 1 Hitoshi Tatebe, M.D. Hitoshi Hajime Monzen, M.D., Ph.D. Takamasa Mitsuyoshi, M.D.
1 Abstract 2013-Present 2012-2013 experience professional and Research 2012-Present 2010-2012 2004-2010 Education (OPC) carcinoma oropharyngeal with patients for (IMRT) therapy radiation intensity-modulated atwo-step of results Clinical advanced NSCLC. Conclusions: and 0.049). 0.045 0.023, = (p significant were CRP pretreatment and sex age, analysis, multivariate In insignificant. was chemotherapy of use the CRP<1.0 but factor, significant marginal with a was stage patients Clinical respectively. CRP>=1.0, and for 26.2% and 43.0% was OS 3-year The 0.009). and 0.012 0.012, = (p index Brinkman and sex age, with along 0.034) = (p OS for factor significant a was level CRP pretreatment the analysis, variate Result: CRP The level. CRP the levels wereunderthethresholdvaluein99patientsandover53. for mg/dl 1.0 of value threshold a set We obtained. was treatment the before level (CRP) protein C-reactive Serum reviewed. retrospectively were records medical their and 2013 June and 1999 Methods: orradiotherapy(RT). with chemoradiotherapy (CRT) treated patients (NSCLC) cancer lung cell non-small advanced locally in (OS) survival overall and (PFS) Objective: in, Sakyo-kuKyoto,606-8507, 1 Takamasa Mitsuyoshi Abstract 2014.4- experience professional and Research 2004-2010 Education cancer lung cell non-small advanced locally for (chemo)radiotherapy after outcomes on inflammation of Impact vary preservationwereobtained.HPVstatusofOPCshouldbeexaminedbeforeradiotherapy patients. the of 15% approximately for noted only was more or 2 grade of xerostomia Long-standing (p=0.0517). patients p16-negative in those for stages I,II,III,andIV,68% respectively. Theoverallsurvivalrateinp16-positivepatientsweremarginallybetterthan and 85%, 80%, 57%, were rates survival overall 5-year The patients. two remaining the for done not was IHC and p16-negative lo were eight 10 noted, was were PTV of there recurrence marginal total, no but recurrences, In co-regional respectively. IV, and III, II, I, stages for 86% and 92%, 80%, 80%, were rates control (p16). 16 type (HPV) papillomavirus human of (IHC) immunohistochemistry patients, 58 For patients. 34 for given was radiotherapy during chemotherapy Concurrent Gy). 70 (median fractions 35 30- / Gy 60-70 of dose total a to volume target clinical risk high the to IMRT boost by followed IMRT, by given was fractions Gy/23-25 46-50 to radiotherapy whole-neck method, step neck two by the treated In were IMRT. more before or dissection cN2b with patients Most IV. stage 41 and III, stage 13 II, patients stage 7 10 were I, There stage years). with 35-84 (range, years 65 of age median a with group women The 15 2013. and and men 2002 56 between included IMRT by treated /5) /10 /17 39 -: superior / rear- / side- / (anterior-wall analyzed. was OPC for IMRT two-step our of results Clinical City, Osaka589-8511,Japan 1 Nakamatsu Hitoshi Tatebe Hitoshi Department of Radiation Oncology and Image-Applied Therapy, Kyoto University Kyoto Therapy, Image-Applied and Oncology Radiation of Department Osaka-Sayama Ohno-higashi, 377-2, Medicine, of Faculty Oncology,University Radiation Kinki of Department The median follow-up time was 18 months (range, 1-109 months). The 3-year OS was 36.6%. In uni In 36.6%. was OS 3-year The months). 1-109 (range, months 18 was time follow-up median The Yoshihito Nomoto, M.D., Ph.D. A total of 152 patients with clinical stage Ⅲ NSCLC were treated with CRT or RT between January between RT or CRT with treated were NSCLC Ⅲ stage clinical with patients 152 of total A We aimed to investigate impact of pretreatment inflammation status on progression-free survival progression-free on status inflammation pretreatment of impact investigate to aimed We
1 Hajime Monzen The pretreatment CRP level can be used as an important predictor for OS in patients with locally with patients in OS for predictor important an as used be can level CRP pretreatment The
1 Kazuki Ishikawa Kazuki Poster Session 1 Medicine KyotoUniversity. of School Graduate Therapy, Image-Applied and Oncology Radiation of Department Shimane UniversityFacultyofMedicine Department ofRadiationOncology, KinkiUniversityFacultyofMedicine,Osaka,Japan Department ofRadiology, NaraHospitalKinkiUniversityFacultyofMedicine,Nara,Japan M.D., FacutlyofMedicine,KinkiUniversityMedicine Resident ,Fukuiprefecturehospital Kinki UniversityFacultyofMedicine 1
, (Kinki University) (Kinki Yukinori Matsuo Radiation Oncology 1 Japan Shuichi Kanamori Chair persons Chair 1 Masaki Yokokawa Masaki
Excellent overall survival and loco-regional control rates with good sali good with rates control loco-regional and survival overall Excellent 1 Masahiko Koizumi, M.D., Ph.D. , Yusuke Iizuka 1 Yasumasa Nishimura 1 Masahiro Inada Masahiro 1 , Takahiro Kishi
This study group included 71 patients with OPC with patients 71 included group study This (Mie University) 1 1 , Takashi Mizowaki Kohei Fukuda Kohei , 1 54 Kawaharacho, Shogo Kawaharacho, 54
Izumi Tachibana Izumi The 5-year loco-regional 5-year The 1 , MasahiroHiraoka (Osaka University) (Osaka . 1 Kiyoshi 1 - - - - 21
Poster Session 1 Poster Session 1 ＭＥＭＯ
22 DAY 2
The 4th International Symposium of Training Plan for Oncology Professionals February 28 (Sun), 2016 Yamato-no-Ma
Poster Session-2
Poster-2 Hematological Oncology/Cancer Stem Cell 9:00-9:20 Poster-3 Developmental Therapeutics 9:20-9:40 Poster-4 Oncology Nursing 9:00-10:00
Oral Session
Session 4 Oncology Pharmacy 10:10 – 11:35 Luncheon Seminar 11:50 – 12:50 Session 5 Thoracic Oncology-2 13:05 – 13:40 Session 6 Gastrointestinal Oncology 13:40 – 14:50
23 , - - - - 1 oma stem /kg and 2.83 x 6 , Shinya Fujita last 1 targets. Nakauchi-cho, Mis , 5 their , RT-PCR RT-PCR analyses, stem cell q . In
1 , Takahisa Nakanishi 1 , and examined their expressions in HA cells and CFU-GM colony. Data about cells and CFU-GM among lenograstim, + maintenance of gliob + 1%) 2
(O suppressed the proliferation of non-CSCs and s hypoxic condition ion transport-associated molecules in GSCs. GSCs ancer cells keep intracellular pH in weak alkaline by , Shosaku Nomura (Osaka City(Osaka University) 1 , Masaaki Hotta 1 or MCT s several , Kazuyoshi Ishii 1 play an important role in cells and CFU-GM in the FLBN group were 4.19 x 10 + , Yoshiko Azuma In order to survive, c 1 CA12 and MCT1 mRNA transcripts were elevated in CSC spheres but not 1 Chair persons , and , Tomoki Ito , Tomoki Immunofluorescent examinations showed that stem cell markers were detect molecules 1 examined examined the expressions of Eishi Ashihara Yukie Tsubokura , 1 Recent evidences suggest that a minor subset of cancer cells, so-called cancer stem cells Kansai Medical University(Osaka, Japan) University Graduate School of Medicine ,Kansai Medical Kyoto Pharmaceutical University graduate school Kyoto Pharmaceutical University Kyoto Pharmaceutical Poster Session 2 Session Poster first first and , Aya Nakaya 1 1 next investigated the effects of the inhibitors on the proliferation of GSC cells. next investigated the effects of the inhibitors Mobilization of peripheral blood hematopoietic progenitor cells (PBPCs) has become a standard In our experience, FLBN cleared the target PBSCs dose for stem cell harvest and showed a We Data were prospectively collected for 12 patients undergoing PBSC mobilization at Kansai Medical The median number of CD34 ancer therapy. Cancer cells produce ATP through glycolysis even under a normoxic condition, and they Hematological Oncology/Cancer Stem Cell Stem Oncology/Cancer Hematological Hirohisa Nakamae, M.D., Ph.D. Ph.D. M.D., Nakamae, Hirohisa /kg, respectively. There were no significant differences in CD34 c 5 SCs. In conclusion, CA12 and MCT1 maintain GSCs and these molecules are promising SCs. In conclusion, CA12 and MCT1 maintain First Department of Internal Medicine, Kansai Medical University Department of Clinical and Translational Physiology, Kyoto Pharmaceutical University (lenograstim, (lenograstim, originator filgrastim and FLBN) with number of CD34 institution. lenograstim and originator filgrastim were retrospectively corrected for patients with our Results: 10 Atsushi Satake 1 Background: procedure in patients prior to an autologous stem cell transplant. Recently, biosimilars have been routinely introduced in clinical practice, in particular in the treatment of cancer neutropenia. In addition, the European Medical Association extrapolated the therapeutic equivalence of the biosimilars for PBSC mobilization. We evaluated the efficacy of filgrastim BS-NK (FLBN) for PBSC mobilization. Methods: University between January 2013 and February 2015 using the FLBN. All patients were hematological malignancies (8 with DLBCL, 1 with FL, 1 with HL and 2 with multiple myeloma). We compared 3 groups filgrastim and FLBN. Finally, the impact of FLBN was evaluated in the engraftment after PBSCs reinfusion. The engraftment. result demonstrated no differences among 3 groups in median days to obtain neutrophil Conclusion: desirable efficacy in shortening the period of neutropenia after autologous stem cell transplantation, with a favorable cost effect for this biosimilar. Research and professional experience 2015.4- Abstract Hideaki Yoshimura maintenance and the functions of CSCs. In the present study, we investigated the expression of (GSCs). port-related molecules in CSCs of GBM cells ion trans [METHODS] were generated using a cancer sphere formation assay. We also established hypoxia-adapted (HA) GBM cells that can be survived and proliferate under a hypoxic condition GBM cells. We [RESULTS and DISCUSSION] ed in cancer spheres and that cancer spheres were in the markers were elevated in GSCs in non-CSC/HA cells. Moreover, the inhibitors of CA C Evaluationof biosimilar a granulocyte colony-stimulatingfactor (filgrastim BS-NK)for peripheral blood stem cell mobilization Education 2004-2010 cells Education 2012- 2006-2012 Abstract Takada Tetsuya 1 Japan Kyoto 607-8414, asagi, Yamashina-ku, [INTRODUCTION] (CSCs), have renewal potential to develop tumors. Therefore, CSCs characterization is important for develop ing generate excessive acidic substances. transporting protons across plasma membranes. Glioblastoma (GBM) is one of the most aggressive human cancers with a low 5 year survival rate. We hypothesize that the ion transport-related molecules regulate the Ion transport-associated M.D. Tetsuya Takada Tetsuya Hideaki Yoshimura, 24
Poster Session 2 Yuka Asano, M.D. Yuka Asano, Yuki Otani Yuki Assessment of structural alterations of Rituximab in rat rat in Rituximab of alterations structural of Assessment sociation between chemotherapy sensitivity and AR expression in patients treated with neoadjuvant chemo neoadjuvant with treated patients in expression AR and sensitivity chemotherapy between sociation as the investigated we study, this In clinic. the in validated substantially been not has this however, cancers; breast receptor-positive hormone other to similar resistant, chemotherapy be to thought are expression Background: School ofMedicine,1-4-3Asahi-machi,Abeno-ku,Osaka545-8585,Japan 1 Noda structural alterationsofrituximabinclinicalstudy. the assess to plan we hence human, in elucidated be to remains variation Interindividual changes. structural slight to due effects pharmacological the influence hardly but observed, were vivo in chains carbohydrate alterations of the that suggested results These assay. vitro in affected not were rituximab isolated of activities CDC and ADCC chains, carbohydrate some in observed were alterations significant Although increased. were GnGnF.GnGn and and MGnF/GnMF AAF of contrast, types In glycosylation the in observed was ratios content Results: in vitro. assessed were rituximab isolated of activities (CDC) cytotoxicity dependent complement and (ADCC) toxicity cyto cellular dependent Antibody analysis. TOF-MS by followed papain, by digested was rituximab isolated Then, antibody. anti-rituximab using plasma from isolated was Rituximab aorta. abdominal via collected was Methods: and relationshipbetweenstructuralchangespharmacologicaleffects. vivo in rituximab of alterations time-dependent the assess to tried we study, this In body. a into administered antibodies therapeutic of alteration structural the about information no is there However, modifications. al post-translation various to due structures heterogeneous have They diseases. autoimmune or cancer for apy Background: 8507, Sciences Pharmaceutical and Pharmacy in Education Integrative of 1 Nakagawa YukiOtani Abstract April 2013-now April 2008-March2010 April 2004-March2008 Education AR-negative phenotypewasobservedafterNAC. TNBC. in NAC to responses treatment predict to markers immunohistochemically. NAC. with treated were cancer breast early-stage resectable regimens. and criteria chemotherapy standardized using (NAC) therapy expression was significantly extended (p=0.006, log-rank). (p=0.006, extended significantly was expression AR for negative were that cases in period non-recurrence the expected, as cases, TNBC In TNBC. AR-negative with those with compared AR-positive with patients in (p=0.008) common more was recurrence disease and (p=0.001), lower significantly was NAC after (pCR) response complete pathological of rate The 88.8%) (p<0.001). (103/116; patients non-TNBC in found that than common less significantly was which (37.7%), 23 in Asano Yuka Abstract April 2003-09 April 2009-March2011 April 2011-March2013 April 2013- Education cancer breast triple-negative positive tor-expressing recep of cases in androgen chemotherapy pre-operative to sensitivity of verification Clinical DepartmentofClinicalPharmacologyandTherapeutics Department of Surgical Oncology, Surgical of Department Eishi Ashihara, M.D., Ph.D. 1 Japan , Tsutomu Takashima Nine kinds of carbohydrate chains in rituximab were detected. Time-dependent decrease of the of decrease Time-dependent detected. were rituximab in chains carbohydrate of kinds Nine designated time points, whole blood Rituximabwasadministeredat10mg/kgintoWistar/STrat.Atdesignatedtimepoints,wholeblood 1 1 , Atsushi YonezawaAtsushi , , Takayuki Nakagawa 1 , Shinichiro Kashiwagi Shinichiro , Avarietyoftherapeuticantibodieshavebeenapprovedandplayanimportantroleindrugther
Triple-negative breast cancer (TNBC) patients testing positive for androgen receptor (AR) receptor androgen for positive testing patients (TNBC) cancer breast Triple-negative
DevelopmentalTherapeutics Poster Session 3 Results: 1 Master coursestudentKyotoUniversityMasterofScienceinPharmacy Undergraduate studentKyotoUniversityBachelorofPharmacydegreereceived Aichi MedicalUniversity, Aichi,Japan Residency, KashiwaraMunicipalHospital,Osaka,Japan Senior Residency,OsakaCityUniversityHospital Osaka CityUniversityGraduateSchoolofMedicine Kyoto UniversityHospital Doctoral course student Department of Clinical Pharmacology & Therapeutics & Pharmacology Clinical of Department student course Doctoral , NaoyoshiOnoda 1 , Satoshi Imai Satoshi , Chair persons Chair 1 and
Sixty-one patients were diagnosed with TNBC; AR expression was identified was expression AR TNBC; with diagnosed were patients Sixty-one 1 , Masakzu Yashiro Masakzu , 2 Kazuo Matsubara Department of Diagnostic Pathology, Osaka City University Graduate University City Osaka Pathology, Diagnostic of Department 1 , Masahiro TsudaMasahiro , 1 , MasahikoOhsawa (Kyoto Pharmaceutical University) 1 , Wataru Goto Wataru , 1
, KyotoUniversityHospital, Moreover, induction of a change in subtype to the to subtype in change a of induction Moreover, Conclusion:
ER, PgR, HER2, Ki67 and AR status were assessed were status AR and Ki67 HER2, PgR, ER, 1, 2 1, , YasuakiIkemi , 2 , KoseiHirakawa 1 , Kento Kurata Kento , , Kyoto University, Kyoto AR expressions may be useful as bio as useful be may expressions AR
Methods: 1 , TomohiroOmura ,
1 A total of 177 patients with patients 177 of total A 1 , TamamiMorisaki ,
2 CenterforDevelopment Sakyo-ku, Kyoto, Sakyo-ku, 1 , Shunsaku , 1 , Satoru , - 606------25
Poster Session 3 ) ------1, 2 for men and 5.7 2 Osaka Prefecture University and Yasushi Miura and Yasushi ( 1 . , Yoshitada Sakai , Yoshitada 2 , Rei Ono 1 (Kinki University Hospital) Kyoko Tanaka, Ph.D., RN RN Ph.D., Tanaka, Kyoko , Miyuki Kashiwa ) 1 Chair persons Oncology Nursing Oncology Physical Therapist, Hyogo Emergency Medical Center Physical Therapist, Hyogo Hospital of Rehabilitation Medicine, Kobe University Physical Therapist, Division , Junichiro Inoue
2 Research Course Cancer Nursing College of Medical Sciences Mie University Faculty of Humanities, Mie University Nagoya University Master’s course, Graduate School of Medicine, Registered Nurse, Mie University Hospital School of Nursing, Faculty of medicine, Mie University Mie Nursing Association Research Assistant, School of Nursing, Faculty of medicine, Mie University Suzuka University of Medical Science, Faculty of Nursing Osaka University Graduate School of Medicine, Division of Health Sciences, Advanced Kobe University, School of Medicine, Faculty of Health Sciences School of Medicine, Faculty of Health Kobe University, School of Health Sciences MS Kobe University Graduate School of Health Sciences Kobe University Graduate Poster Session 4 Session Poster 1, 2
, H. Arao 1 Fumiko Koyama, MSN, RN RN MSN, Koyama, Fumiko Osaka City Hospital General ( for women) and low physical functions according to Asian Working Group for Sarcopenia. Low physical 2 Osaka Osaka University Graduate School of Medicine, Division of Health Sciences, Advanced Research Course of Osaka university Graduate School of Medicine, Division of Health Sciences the mother’s role were “lower activity affected by general fatigue”, “affect to prepare meals because and “hesitation to attend school events because of hair loss”. sea” of nau Conclusions: Oncology nurses must be aware of the mother’s needs and assist them in reducing the side effects of chemo therapy. 1 Osaka 565-0971, Japan Suita City, Cancer Nursing, 1-7, Yamadaoka, 2 Purpose: To explore the components of the mother’s role during chemotherapy for breast cancer and the factors that in hibit their role because the incidence of breast cancer has been increasing among women with young children. Methods: Semi-structured interviews were conducted with 5 mothers with young children; they were receiving outpa tient treatment with adjuvant chemotherapy in breast cancer. This study was approved by the ethical committee. institutional Results: The mean age of the women was 44.4 years, and they each had two 4–17).Nine major children themes were (mean identified (six maternal age roles and 12.5 three inhibiting years, factors). Components of range, the mother’s role while receiving outpatient chemotherapy included “understanding the pattern of side effects condition”, physical their with dealing while role their “performing chemotherapy”, the next for preparing and “helping their children transition to the new role”, and “reaffirming their role and considering the potentially changed role”. Negative aspects included “feeling sorry about not being able to be a good mother”; however, “the presence of their children during chemotherapy provided them mental resilience”. The factors inhibiting The influence of adjuvant chemotherapy on the role of a mother in breast cancerpatient Education 1996 2004 2008 2013-present Research and professional experience 1996-2002 2004-2006 2009-2012 2012-2014 2014-present Abstract K. Inoue The number of geriatric patients with esophageal cancer has been increasing. The geriatric syndromes such as sarcopenia might affect postoperative recovery adversely. The aim of this study was to lationship evaluate between the sarcopenia re and postoperative pulmonary complications in esophageal cancer patients following esophagectomy. One hundred four patients who underwent esophagectomy from June 2011 to April 2015 participated in this Preoperative sarcopenia was diagnosed by the presence of low muscle mass (7.0 kg/m study. kg/m of grip strength (< 26 kg for men and < 18 kg for women) and/ functions were defined by the presence of loss or slow walking speed (< 0.8 m/s). Postoperative pulmonary complications were defined according to Society the of Thoracic Surgeons guidelines. Both univariate and multivariate analyses were performed for post operative pulmonary complications. Twenty-nine patients (27.9%) were diagnosed as sarcopenia. The incidence of postoperative pulmonary com plications was significantly higher in the sarcopenia group (37.9%) than in the non-sarcopenia group (17.3%) (P=0.04). Multivariate analysis showed that sarcopenia [odds ratio 3.13; 95%CI 1.12 - 8.93] and high Brinkman index [odds ratio 3.46; 95%CI 1.20 – 11.77] were the independent risk factors for the development of pulmo nary complications. To assess sarcopenia would be useful to predict postoperative pulmonary complications in esophageal can before esophagectomy cer patients. Sarcopenia should be evaluated Preoperative sarcopenia is a predictor of postoperative pulmonary complications in esophageal cancer patients following esophagectomy Education 2004-2008 2008-2010 2010-preseent Research and professional experience 2009-2011(part-time) 2011-present Abstract Daisuke Makiura Division of Rehabilitation Medicine, Kobe University Hospital, 7-5-2, Kusunoki-cho, Chuo-ku, Kobe, Hyogo 650-0017, Japan Suma-ku, Kobe, Hyogo 654-0142, Japan 7-10-2, Tomogaoka, Kobe University Graduate School of Health Sciences, Kayo Inoue Daisuke Makiura Daisuke Koji Takeda, M.D. M.D. Takeda, Koji 26
Poster Session 4 Koji Takeda, M.D. Rieko Nakamura Yumiko Kagawa Yumiko Rieko Nakamura Abstract 2013-present 1996-2012 experience professional and Research 2013 1994-1996 Education byafatinib induced paronychia of Nursing severe casesofCRF. Conclusion: life alsoimproved. Result: compared. Quality oflifewascomparedbefore andafterintervention.Theinterviewdatawereanalyzedqualitatively and scores breathings deep for calculated was rate Enforcement week. sixth the through week first the from scores with compared was one week at score median the and calculated were exercise and CRF method. evaluation and program the about patients the interviewed We intervention. the after and before questionnaire life of quality Cancer of Treatment and Research for Organization European the by measured was life of quality addition, In weeks. six for degree breath deep and exercise, of state enforcement coping fatigue. for with self-effect enhance may patients that concerned were We day. every exercises breath deep do participated. Scale Fatigue Cancer the Method: examine theapplicabilityandevaluationmethodofprogram. Purpose: 2 1 Yumiko Kagawa Abstract 2012- 2003-2012 2000-2003 experience professional and Research 2015 Education Fatigue Cancer-Related for program aNursing on study aPilot of Evaluation Qualitative tial todoearlyinterventionsbynursingstaffsinordersucceedthetreatmentwithafatinib. essen is It time. same the at caregivers their and patients both direction provide should staffs nursing feeling, caregivers’ Considering background. patients’ to according important is self-cares for lead carefully Individual Conclusions because ofherowncares. reduction dose further without continued was treatment Her 2paronychia. 1 after grade from time suffered the she months, On skill. taping the including care skin intensive advised was she introduced, was afatinib after Just occurrences. everyday of note kept and fragile, very was She mg/day). (30 afatinib with treated was NSCLC IV stage with female, 77-years 3; Case reduction. dose without continued was afatinib and improved, The steroid. of was paronychia Her misunderstanding. any up clear to ointment steroid with treat to instructed team medical application performing avoid to style, own her after done were self-cares active the an nurse, was working she Because months. 9 for mg/day) (40 afatinib received was lobectomy, the after metastasis ed, histreatmentwascontinuedwithcollaborationofwife’sefforts.Case2;46-yearsfemale,multiplebone need were afatinib of reduction dose and cessation Although wife. his nursing with taping the the him introduced paronychia, staffs severe developed he When best. his do to him wanted wife his Contradictory, care. self- for unmotivated felt and depression, from suffered He mg/day). (40 afatinib with motherapy,treated was che doublet platinum subsequent and gefitinib received who NSCLC, IV stage with male old 56-years 1; Case Results carefully. Threecasesofparonychiainducedbyafatinibwerereviewedretrospectively. considered also were concerns social and state psychological individual Furthermore, techniques. self-care about instructed were patients as well as Caregivers paronychia. of prevention intensive more do to team ical med the offered continuously,and conditions nail and skin their evaluated staffs nursing The pharmacists. or oncologists from explanation the to adding specifically, care, skin about guidance gave staffs nursing the nib, When patientswithadvancedlungadenocarcinomaharboringactiveEGFRmutationdecidedtoreceiveafati Methods expect tobebetteroutcomesforpatientstreatedwithafatinib. staffs nursing and pharmacists dermatologists, oncologists, by paronychia of prevention Intensive treatment. discontinuing and skipping in result toxicity these and paronychia, including toxicity, skin sever develop afatinib with treated patients of Most blocker. family ErbB irreversible an as of characterized generation is second which a EGFR-TKI, is Afatinib (TKI). inhibitor kinase tyrosine EGFR is (EGFR) receptor factor growth mal epider activating harboring (NSCLC) cancer lung cell non-small with patients for treatment standard The Background matology Nursing of Department OsakaPrefectureUniversity, SchoolofNursing,3-7-30Habikino-city, Kyoto MinirenCentralHospital
( Osaka City General Hospital City Osaka Five participants completed the self-report questionnaire. CRF decreased in all five people. Quality of Quality people. five all in decreased CRF questionnaire. self-report the completed participants Five Fumiko Koyama, MSN, RN
We developed a nursing program for cancer-related fatigue (CRF). A pilot study was conducted to conducted was study pilot A (CRF). fatigue cancer-related for program nursing a developed We Participants: 4 , OsakaCityGeneralHospital This program may be effective to decrease CRF. However, this program may not be effective for effective be not may program this However, CRF. decrease to effective be may program This Measurement: 1 1 , NamikiKitada Poster Session 4 ,RyokoSugimoto Nurse, OsakaCityGeneralHospital Nurse, OsakaCitySumiyosiHospital center kobe association nursing Nursing,Japanese Chemotherapy Cancer in Nurse Certified Osaka MunicipalSumiyosiNursingSchool Osaka PrefectureUniversity Ehime University Gifu University Osaka PrefectureUniversity, GraduateSchoolofNursing(PhD) for continuingeducation Seven cancer (five colon cancer and two breast cancer) patients with a score >16 on >16 score a with patients cancer) breast two and cancer colon (five cancer Seven 1 , Department of Medical Oncology Medical of Department , Oncology Nursing We used a self-report numeric rating scale (11 phases of 0–10) to record fatigue, record to 0–10) of phases (11 scale rating numeric self-report a used We 1 , Yoshiko Ueoka Chair persons Chair 2 ) , AkiraNozaki Kyoko Tanaka, Ph.D., RN Program: 1 , HarukoDaga 2 Patients were instructed to walk > 90 minutes/week and minutes/week 90 > walk to instructed were Patients , KyokoTanaka (Kinki University Hospital) University (Kinki 2 , Department of Pharmacy of Department , 2 , Tetsuya Yoshida 1
Osaka, 583-8555,Japan 3 , ShuichiKuniyuki ( Osaka Prefecture University Prefecture Osaka 3 , Department of Der of Department , 4 , KojiTakeda Analysis: . 2 ------)
27
Poster Session 4
) ------Naga Osaka 7 2 6 Emi Nagai Takarazuka
6 4 . Takarazuka Takarazuka City 5 ,Satomi Yshida 5 Osaka Prefecture University Nozomi Yoshida ( 5 Kyoto City Hospital, 3 ,Kozue Yosida 4 Hiroko Sakuma 4 Miyazaki Prefecture NOBEOKA Hospital, 6 ,Yumi Tanaka ,Yumi 3 (Kinki University Hospital) Japanese Red Cross Kyoto Daiichi Hospita, 4 Kozue Yoshida 3 , Megumi Negishi 2 Kyoko Tanaka, Ph.D., RN RN Ph.D., Tanaka, Kyoko ) 8 Chair persons Yuko Matsumura Yuko 2 Kobe City Medical Center General Hospital, 2 Oncology Nursing Oncology Kobe City College of Nursing National Kyushu Cancer Center National Kyushu Cancer in Cancer Certified Nurse Specialist Kobe City College of Nursing Ninety-six cancer patients or their families who visited a cancer nursing OPD in 8 Seirei Yokohama Hospital, 3 Shizue Suzuki 8 and Yoshie Tokuoka and Yoshie Kobe City College of Nursing Kobe City College of Nursing Graduate School Osaka City Juso Hospital Kyoto University Hospital Kochi Woman’s University, Graduate school of Nursing, Master’s course Graduate school of Nursing, Kochi Woman’s University, school of Nursing, Doctoral course University of Kochi Graduate Poster Session 4 Session Poster 1 Kansai Medical University Hirakata Hospital, 5 In the Kobe City College of Nursing Graduate School Certified Nurse Specialist (CNS) Course in Setsuko Umeda 1 Cancer patients or their families undertook an assists necessary to live on with cancers and were On October 18, 2014, we invited a liaison nurse, a CNS in Psychiatric Mental Health Nursing, as a vis The purpose of this study was to clarify the participants’ learnings from the ongoing training pro The purpose of this study is to clarify the outcomes of cancer nursing by oncology clinical nurse The response rate was 72%. The purposes of their clinical visits were 1) acquisition of more detailed The questionnaires yielded data on the participants’ learning phases of counseling techniques, which
Fumiko Koyama, MSN, RN RN MSN, Koyama, Fumiko Osaka City Hospital General ( Etsuko Inokuchi 7 Kobe City College of Nursing, 3-4 Gakuennishi, Nishi-ku, Kobe-city, Hyogo, 651-2103, Japan, Kyoto University Hospital, oneself,” oneself,” “Awareness of perspective gaps in problem-solving.” Participants deepened their learnings, citing “Awareness of emotions of oneself and other CNS’s through process recording, and learning how to interact with each other,” “Understanding the patient’s viewpoint through role-playing,” “Encouraging patients to “Understanding and utilizing concrete thought express their feelings, so that they may be better understood,” processes of other CNS’s,” “Deepened understanding of counseling techniques and their application in com Learning phases were further divided into twenty three subcategories. munication.” These findings indicate that role-playing, process recording, and peer discussion were effective in improving counseling techniques for cancer patients. In 2014, we held a training program with the theme, “Acquiring Advanced Counseling Techniques.” The train Advanced Counseling Techniques.” In 2014, we held a training program with the theme, “Acquiring below ing program clarified the participants’ learnings and their future challenges, as reported Purpose: the in students graduate Nursing, Cancer in CNS’s by held was which techniques; counseling improve to gram CNS Course in Cancer Nursing, as well as graduates of the CNS Course in Cancer Nursing. Methods: iting lecturer and held an all-day training program (including a lecture, role-playing, and process recording). Three ongoing training programs were held (Nov.15, 2014; Jan.17, 2015; Mar.14, 2015), in which, participants were divided into small groups and performed role-playing based on each individual’s process recording. Af terword, the contents of each role-playing were discussed. We surveyed questionnaires in which participants described their learnings and reflections in a free after each training program, and again, upon the completion of all programs. format, Qualitative inductive analysis was used to clarify the learning phases of participants who attended the whole program: 8 CNS’s, 1 graduate, and 2 graduate students. Results: were analyzed using qualitative inductive methods. Nine categories of learning phases were identified. Partic ipants reflected on categories such as: of “Awareness one’s own tendencies in “Understand communication,” ing previously unperceived thoughts and sufferings of the patient,” “Awareness of inconsistencies within 1999-2001 2007-2009 Research and professional experience 2001-2008 2010- Abstract Hiroko Sumi shi 1 City Hospital, saki University Hospital , Background: Cancer Nursing, the graduate members have held study sessions on a regular basis in order to improve practi cal CNS skills, develop various roles, and to build networks. For the three years starting in 2014, as part of the 7-University Joint Project, we based on a course for reinforcing practical skills for CNS in Cancer Nursing. planned a training program Activities to Improve Counseling Techniques for Cancer Patients Education specialists in an outpatient department (cancer nursing OPD). specialists in an outpatient department (cancer Patients and Methods: eleven hospitals were included in this study. A questionnaire concerning their purposes of clinical the visit, extent and of their satisfaction and emotional changes after utilization of cancer nursing OPD was statistics. collected data were analyzed by a descriptive used. The Results: a life under medical treatment and 3) obtaining knowledgeinformation of treatments, 2) consultation regarding about methods to relieve pains or symptoms in order of percentage. Seventy-three % and 26% of the patients or their families answered “I am very satisfactory” and “I am somewhat satisfactory” after the visits, respectively. Their emotional changes after the visits were expressed as following comments: 1) “I could have more positive state of mind for receiving medical treatments”, 2) “I could get a feeling to and 3) “My anxieties were relieved or removed”, in order of percentage. against a distress or worrisome”, have more independent action Conclusion: eventually empowered by utilizing cancer nursing OPD. Furthermore, high level of positive evaluations to OCNS by them was suggested in this study. Outcomes of cancer nursing by oncology certified nurse specialist in outpatient (OCNS) department Education 2004-2006 2014-present Research and professional experience 1996-2000, 2006-2010 2007 2010-present Abstract Ryoko Takayama 1 Prefecture University, Hospital ,6Shiga medical center for adult Purpose: Hiroko Sumi Hiroko Ryoko Takayama Ryoko Koji Takeda, M.D. M.D. Takeda, Koji 28
Poster Session 4 Tatsuya Nishioka methods. InJapan,weneedtoemphasizeourroleand importance. optimal using activities own their report and evaluate pharmacists whether is question US. important most The the in that to similar is work our of quality the that consider we Therefore, effectiveness. our report to sufficient not is information the but support), prescription as (such approaches other utilized we addition, In cases. the of (28%) 35 in changed were prescriptions and PIMs, of cases 125 identified We criteria). STOPP the (using identified were 81) = n (26.9%; PIMs taking patients Study patients). cancer for only (not stitute in our in PP against intervention pharmacist’s of effectiveness the reported also We common. is approach multidisciplinary but Japan, in incentives institutional many not are there hand, other the On respectively). patients, study the of 51% and (41 (PIMs) medications inappropriate potentially of use the and PP of lence preva high a demonstrated assessment medication comprehensive pharmacist-led a that shows report a (PP), polypharmacy Regarding pharmacists. by patients 75% over to made reportedly are recommendations specific and visit, first the at performed is assessment geriatric multidisciplinary a field, oncology geriatric the in Especially used. actively is approach multidisciplinary a addition, In practice. clinical and institutions al as CDTMandtheavailabilityofapharmacytechnician),reiscloserelationshipbetweeneducation (such incentives institutional several are there TJU, At Philadelphia. in (TJU) University Jefferson Thomas the at training during obtained information the on based US, the and Japan in pharmacists between activities in differences the considered We changing. dynamically been have pharmacist oncology the of activities The 1 Masaaki TandaMasaaki of ClinicalThe Activity Oncology Pharmacist in the US and Japan: Especially Intervention DepartmentofPharmacy, KobeUniversityHospital;7-5-2Kusunoki-cho,Chuo-ku,Kobe,650-0017, Japan Session 4 Masaaki Tanda Masaaki 1 , Naomi Mizuta Naomi , Chair persons, Pharmacy Oncology 1 , ManabuKume 1 in Elderly Patients and Polypharmacy. , Mamoru Okuno Mamoru , Education 2012-present 2009-2012 experience professional and Research 2007-2009 2003-2007 1 , HirooMakimoto Tomohiro Terada, Ph.D. Midori Hirai, M.D., Ph.D.
Hospital, Kobe East, Chiba Pharmaceutical Sciences,Osaka Pharmaceutical Sciences,Osaka Pharmacy staff, Department of Hospital Pharmacy, Kobe University Kobe Pharmacy, Hospital of Department staff, Pharmacy Hospital Center Cancer National Pharmacist), (Hospital Residency of University Osaka Sciences, Pharmaceutical of School Graduate ofUniversity ,Osaka Sciences Pharmaceutical of Faculty 1 , Shiori Aoki Shiori , Abstract 1 andMidoriHirai 1 , TakeshiKimura ,
(Shiga of University Medical Science Hospital)
(Kobe University) (Kobe 1 1 , Fumie Ogura Fumie , 1 , Atsushi Uda Atsushi , 1 - - - , 29
Session ４ (Kobe University)
(Shiga University of Medical Science Hospital) Science Medical University of (Shiga
Department of Pharmacy National Taiwan University Hospital Department of Pharmacy National Taiwan University Hospital Department of Pharmacy National Taiwan Department of Pharmacy National Taiwan University Hospital Department of Pharmacy National Taiwan University Hospital Department of Pharmacy National Taiwan Outpatient pharmacy Outpatient pharmacy Inpatient pharmacy of Illinois Medical Center at Chicago Visiting pharmacist University Outpatient pharmacy Section Chief of Clinical Pharmacy Abstract Department of Pharmacy National Taiwan University Hospital School of pharmacy, College of Medicine, National Taiwan University National Taiwan College of Medicine, School of pharmacy, Graduate institute of Clinical pharmacy, College of Medicine, (Bachelor of Science) in Clinical Pharmacy) University (M.S. National Taiwan Clinical Pharmacist in Hematological Oncology
Midori Hirai, M.D., Ph.D. M.D., Hirai, Midori Tomohiro Terada, Ph.D. Terada, Tomohiro 2014 Sep – 2015 Sep 2010 Apr -2010 Oct - Oct 2010 2005 2007 Research and professional experience 2007 Aug-2008 Aug 2008 Sep-2009 Sep 2009 Oct - 2010 Mar Education Should therapeutic monoclonal antibodies in oncology be oncology in antibodies monoclonal therapeutic Should
Oncology Pharmacy persons, Chair dosed based on body surface area, body weight, or nothing (flat dose)? (flat nothing or area, body weight, body on surface based dosed 4 Session Yu-Wen Wang, Ph.D. Wang, Yu-Wen I will review the dosing strategy of therapeutic monoclonal antibodies currently approved in oncology and discuss the pros/ cons of each dosing strategy. the phase I trial. The current practice of using body surface area (BSA), body weight, or nothing (flat dose) in dosing anticancer monoclonal antibodies varies from one to another. For example, cetuximab is dosed based on BSA. Rituximab could be dosed on BSA or using flat dose. Pembrolizumab is flat dosing. In this talk, including monoclonal antibodies. The ideal (recommended) dose for a specific patient is the highest dose associated with an acceptable toxicity. This dose is known as the maximum tolerated dose determined in Department of Pharmacy, National Taiwan University Hospital, Taipei, Taiwan Taipei, University Hospital, Taiwan National Department of Pharmacy, Adequate drug dosing is a key issue in oncology due to the ‘dose-effect’ relationship of anticancer agents, Yu-Wen Wang Yu-Wen 30
Session ４ velop theidealmedicalteamcare,itseemsprudent to reviewthecurrenteducationalsysteminJapan. de To increase. will change of pace the and inevitable is pharmacy in sub-specialization towards move The members ofthemedicalteam. essential are they practice; into (CDTM) Management Therapy Drug Collaborative put and patients), for ate appropri more are that prescriptions suggest they (where conferences case join knowledge, high-level gain to time have BCOP consequence, a As efficiencies. operational been have there technicians of troduction in the with and specialized, and strictly more divided is work America, In guidance. patient to preparation drug from duties, all covers everyone work; our divide not do we hospital, our At theirs. against practice our reviewed have I then, Since professionally. work (BCOP) Pharmacist Oncology Certified Board American how learned I Department. Pharmaceutical Hospital University Michigan the visit to opportunity an had ly recent I knowledge. and experience my utilize JOP,to a how as considered certification completed I Having these activitiesdependsontheinstitute,andisnon-standardized. of variety the that observed been has it fees, guidance patient cancer of establishment the promoting While examination. doctor to prior reviews medicine pharmacist-led example, for diverse, more become have duties Their (JOP). Pharmacists Oncology (JSPHCS)-certified Sciences and Care Health Pharmaceutical of Society Japanese specifically more 2015, during 400 exceeded pharmacists oncology clinical of number The 8686 Japan 1 Kanae Hanafusa Pharmaceutical Department, Osaka Medical College Hospital, 2-7, Daigaku-machi, Takatsuki, Osaka 569- Osaka Takatsuki, Daigaku-machi, 2-7, Hospital, College Medical Osaka Department, Pharmaceutical Session Kanae Hanafusa Kanae 4 Chair persons, Pharmacy Oncology 1 Oncology pharmacist activities in Japan and America Education April 2011-present experience professional and Research March 2006 March 2011 April 2007-January2009 February 2009-March2011 Tomohiro Terada, Ph.D. Midori Hirai, M.D., Ph.D. Bachelor ofPharmacy, OsakaUniversity (Osaka, Japan) Master ofPharmacy, MukogawaWomen’s University(Hyogo,Japan)
Abstract University Hospital Sciences, KyotoUniversity Department, OsakaMedicalCollegeHospital Pharmaceutical Pharmacist: Oncology (JSPHCS)-certified Japanese Society of Pharmaceutical Health Care and Sciences Clinical Pharmacist: Pharmaceutical Department, Kobe Department, Pharmaceutical Pharmacist: Clinical Pharmaceutical of School Graduate Staff: Teaching Assistant
(Shiga of University Medical Science Hospital)
(Kobe University) (Kobe - - - - 31
Session ４
’ Seoul, 06351, Rep of Korea
(Kobe University)
(Shiga University of Medical Science Hospital) Science Medical University of (Shiga
tighten up regulations on investigational drug good quality of infrastructure, such as medicinal Phase I~II, oral pan-HER inhibitor in advanced gastric cancer Phase I~II, oral pan-HER oral ALK inhibitor in mNSCLC Phase III, Global, Multi-center, Phase III, Global, Multi-center, anti CD38 inhibitor in relapsed or or refractory MM(currently involved in about 300 trials as a clinical trial pharmacist) Abstract 81 Irwon-ro, Gangnam-gu, , authorities maintain The Collaborative Institutional Training Initiative (CITI) GCP training Training The Collaborative Institutional Qualified Clinical Research Pharmacist/Korea National Enterprise for Center e-IRB program of Samsung Medical GCP training via on-line Medical Center 7th GCP course of Samsung Clinical trials Midori Hirai, M.D., Ph.D. M.D., Hirai, Midori Tomohiro Terada, Ph.D. Terada, Tomohiro Nov.2012 Sep.2013 Mar.2014 Aug.2015 Research and professional experience Apr.2014-Present Apr.2014-Present Apr.2014-Present Education Samsung Medical Center
Investigational drug management and current issues current and management drug Investigational
Oncology Pharmacy persons, Chair In addition to the number of clinical trials and novel therapies increase rapidly in oncology, trial
4 Session nvironment of pharmaceutical industry is evolving rapidly and clinical trials are at the center of these Hyekyoung Eum, HyekyoungPh.D. Eum, Clinical research is a vital part of improving treatments for patients. Pharmacists need to be comprehensive of all aspects of the clinical trial process to serve their best roles and be prepared for changes in the field of clinical trials, thereby optimize patient care ultimately. about the requirement of a clinical trial, medication dosing and administration, anticipated side effects and storage, etc. Additionally pharmacists should or temperature monitoring devices, meets all standards. freezer, refrigerator, the approved current protocol and relevant regulations. All of these procedures have to be documented and be prepared for monitoring, audit, or inspection. Pharmacists also counsel patients receiving IMPs services. The pharmacy may support clinical trials involving medicines, biological substances, cell or gene therapy. Pharmacists are responsible for ensuring investigational medicinal products(IMPs) are appropriate to use and are procured, labelled, dispensed, stored, destructed or returned to sponsors in accordance with settings. pharmacists Moreover, have been increased in complexity and diversity. designs and requests from sponsors role has been more complicated since related E changes. Pharmacists have become an integral part of clinical research support in a variety of practice Clinical Trial Pharmacy, Clinical Trial Hyekyoung Eum, Pharmacist 32
Session ４ ings willprovidecriticalinsightsforthedevelopment ofcancer-targetingtechnology find These tropism. cell this with carrier drug artificial an give to lipids unique these believe We cells. cancer U251 of components U251 of interaction ligand protein of lack the in seen still was and cells recipient of ity activ phagocytotic the to owing not was phenomenon This cells. non-cancer into than cells cancer of kinds (U251 exosomes glioblastoma-derived identified We tact exosomes. in of movement unique the indicating clearly reports few are there Nevertheless, transport. efficient their be also could tropism cell exosomes, of stability this to addition In cells. distant to proteins and miRNAs convey and fluid body our of all in present which nanovesicles released extracellularly are somes Exo idea. targeting novel a construct us help could communication cell-to-cell of mechanism The hard. technically also is carrier of surface the on decoration Protein trials. advanced of tolerable is which potential, targeting a had not have they however, selectivity; with carrier drug the honor to ligands their expected and proteins cancer-associated some highlighted studies clinical and basic many far, So safer. and effective more chemotherapy anti-cancer current the make to technology promising a be must Cancer-targeting University Japan 607-8412, Kyoto ina-ku, 1 Yuki Toda Department of Medicinal Chemistry, Kyoto Pharmaceutical University Misasagi-Shichono-cho 1, Yamash 1, Misasagi-Shichono-cho University Pharmaceutical Kyoto Chemistry, Medicinal of Department Session 4 Yuki Toda 1 , KenichiAkaji Chair persons, Pharmacy Oncology exo The Challenge to Cancer-Targeting using Exosomes differed from those of astrocyte-derived exosomes which were not internalized into internalized not were which exosomes astrocyte-derived of those from differed 1 and Eishi Ashihara 2 ,
Department of Clinical and Translational Physiology Translational and Clinical of Department Education 2015 2012-present experience professional and Research 2012-present 2006-2012 Tomohiro Terada, Ph.D. Midori Hirai, M.D., Ph.D.
2
student guest a as Germany) (Leipzig, Leipzig Universität Psychology, (Kyoto, Japan) (Kyoto, Japan) received Graduate School of Pharmacy, Kyoto Pharmaceutical University Pharmaceutical Kyoto Pharmacy, of School Graduate University Pharmaceutical Kyoto Pharmacy, of School Graduate Pharmacy -B.S., Japan) (Kyoto, University Pharmaceutical Kyoto Institute of Biochemistry, Faculty of Biosciences Pharmacy & Pharmacy Biosciences of Faculty Biochemistry, of Institute Abstract exo ) that were more effectively internalized into some into internalized effectively more were that )
(Shiga of University Medical Science Hospital)
(Kobe University) (Kobe , . Kyoto Pharmaceutical Kyoto exo with cells. The lipid The cells. with c rucial to rucial - - - - - 33
Session ４ year of Sr. Highschool) of Sr. year rd – 3 st Chair Image-applied Therapy, Therapy, Image-applied Masahiro Hiraoka, M.D., Ph.D. Ph.D. M.D., Hiraoka, Masahiro Speaker : Hirotsugu Kenmotsu, M.D. Kenmotsu, : Hirotsugu Speaker Kyoto University Graduate School of Medicine of School Graduate University Kyoto Division of Thoracic Oncology, Shizuoka Cancer Center Shizuoka Division of Thoracic Oncology, Luncheon Seminar Professor and Chair, Department of Radiation Oncology, Oncology, Radiation of Department Chair, and Professor Fujisawa MunicipalFujisawa Hospital medicine) (Internal Fujisawa City UniversityYokohama (Residency Hospital of medicine) Internal Yokohama Yokohama City (Majoring in Medical UniversityYokohama Science) Yokohama Highschool) (1 Fujisawa Shonan Highschool (Sr. Shizuoka Sunto-gun Cancer Center (Deputy senior staff) National Hospital Cancer Center East Kashiwa (Residency of medical oncology) medicine)Kanagawa (Internal Cardiovascular and Respiratory Yokohama Diseases Center. Shizuoka General Hospital Shizuoka medicine) (Internal Topics of NSCLC treatment and future direction future and treatment NSCLC of Topics DAY 2 DAY Japanese Society of Medical / Specialist Oncology Japan) (Shinjuku-ku, Tokyo, Japanese Society of Allergology / Specialist Japan) (Taito-ku, Tokyo, American Society of Clinical Oncology ) USA (Alexandria, VA, Japanese Cancer Association Japan) (Shinjuku-ku, Tokyo, Board certification/ Medical license: The Japanese Society of Medicine Internal (Bunkyo-ku, / Certified Japan) Tokyo, Physician The Japanese Respiratory Society (Bunkyo-ku, / Specialist Japan) Tokyo, - 2003 2001 - 2001 1999 2010 - present 2010 - 2010 2007 2005 - 2007 - 2005 2003 1989-1992 ExperienceWork Education 1993-1999 34
Luncheon Seminar 2014-present 2014-present 2014-present 2014-present EMPLOYMENT HISTORY 2011-2014 2010-2014 2009-2010 2002-2009 1998-2002 EDUCATION &TRAINING Circulating biomarkers for personalized treatment of lung DAY 2
Assistant Professor, Department of Medical Biophysics, University of Toronto of University Biophysics, Medical of Professor,Assistant Department Toronto of Oncology, University Radiation of Professor,Assistant Department Network Health University Institute, Centre Research Cancer Margaret Princess Scientist, Network Health Centre, Cancer Margaret University Princess –Clinician Scientist, Oncologist Radiation Staff Dates: 1, July 2011 30, –June 2014 USA CA Stanford, Institute, Cancer Stanford Fellow, Oncology Radiation Postdoctoral Dates: 1, July 2010 30, –June 2014 USA CA Stanford, Institute, Cancer Stanford Oncology Radiation (PGY II-V), Residency Dates: 24, June 23, –June 2010 2009 Center, Medical Francisco, USA San Pacific CA California Internship (PGY I), Internal Medicine May 20,Graduated: 2014 York, New Physicians USA of NY Surgeons, and College University Columbia Training Scientist M.D.-Ph.D. Program Medical 4, June 2002Graduated: USA NJ Princeton, Princeton University, Biology Molecular A.B. Princess MargaretCancerCentre,DepartmentofRadiationOncology Professor and Chair, Department of Radiation Oncology, Luncheon Seminar Luncheon Kyoto University Graduate School of Medicine and head and neck cancers Speaker :Scott Bratman, M.D., Ph.D. Masahiro Hiraoka, M.D., Ph.D. University ofToronto, Canada Image-appliedTherapy, Chair , 35
Luncheon Seminar
- - , 2 1 , and Kazuto Nishio Genome Biology and 3 2 Department of (Osaka City University) (Osaka
(Kansai Medical University) Medical (Kansai
, Tetsuya Mitsudomi , Tetsuya 2 , Kazuko Sakai 3 Abstract Genome Center, Kinki University Life Science Research Institute Kinki University Genome Center, Ph.D. in Medicine, Kinki University Faculty of Medicine Ph.D. in Medicine, Kinki Our experimental findings suggest that RTK mutations are not
, Katsuaki Sato 2 Takayasu Kurata, M.D. Kurata, Takayasu Naruo Yoshimura, M.D. Yoshimura, Naruo 2015 Research and professional experience 2015.4-Present Education lung cancer: double-edged sword of DDR2 of sword double-edged cancer: lung , Yosuke Togashi , Yosuke 1
Thoracic Oncology-2 persons, Chair Ph.D. 5 Functional analyses of mutations in receptor tyrosine kinase genes in non-small cell cell non-small in genes tyrosine kinase receptor in mutations of analyses Functional Masato Terashima, Masato Terashima, Session Genome Center, Kinki University, Life Science Research Institute, Thoracic Surgery, Kinki University Faculty of Medicine, 377-2, Ohno-higashi, Osaka-Sayama City, Osaka 589- after treatment with a proteasome inhibitor. always suitable as therapeutic targets. The DDR2 E655K mutation can play a role in cancer progression by cancelling the growth inhibitory effect of collagen. tion decreased cellular proliferation through p38 activation in the DDR2 wild-type-overexpressed cell lines, whereas the growth suppressive effect was lost in DDR2 E655K-overexpressed cell lines. Furthermore, the DDR2 E655K protein bound to ubiquitin ligase E3 (Cbl-b), and the mutant protein expression was increased FGFR1 A263V). These mutations did not exhibit any transformational activities. Neither the phosphorylation nor the protein expressions of RTKs were changed by the DDR2 H246R, ERBB4 D245G, and FGFR1 A263V mutations, although the expression level of the DDR2 E655K protein was particularly low. Collagen stimula NRAS, 1; BRAF, 2), and mutations in PI3K pathway genes were found in 3 samples (PIK3CA, 1; PTEN, 3). Among the mutations in RTKs, the functions of 4 mutations were unclear (ERBB4 D245G; DDR2 H246R and E655K; target-resequenced using NGS. We then investigated the functions of the identified RTK gene mutations, including their oncogenic potential, in vitro. Mutations in RTK genes were found in 20 samples (EGFR, 15; ERBB4, 1; ALK, 1; DDR2, 2; FGFR1, 1), mutations in MAPK pathway genes were found in 9 samples (KRAS, 7; This study investigated whether mutations of receptor tyrosine kinase (RTK) genes detected using next-gen This study investigated whether mutations eration sequencing (NGS) are suitable therapeutic targets. Fifty surgically resected NSCLC samples were 3 8511 Masato Terashima 1 36
Session ５ system metastasesisanemergingproblemaseffectivetreatmentsareavailabletocontrolsystemicdisease. nervous central of control The course. disease patient’s a over control disease maximize to identified be to has treatments of sequence appropriate The patients. in assessed be to need will that strategies treatment new inform will and elucidated be to beginning just are inhibitors kinase tyrosine EGFR newer these to resistance of mechanisms The inhibitors. kinase tyrosine EGFR to resistance acquired and cancers lung tant new third-generation EGFR TKIs are currently underway and demonstrate efficacy in patients with EGFR-mu of trials Clinical patients. in promise showing few with assessed been have strategies treatment different Many cancers. lung oncogene-addicted of treatment the for paradigm a as serve cancers lung EGFR-mutant Street, NewYork, NY10065 66 East 300 Center, Cancer Kettering Sloan Memorial Medicine, of Department Service, Oncology Thoracic Helena Yu Session Helena Yu, M.D. 5 Chair persons, Oncology-2 Thoracic Advances in the treatment of EGFR-mutant lung cancers. Positions and Employment and Positions 2003 2003-2004 2006-2007 2007 2007 2011- 2012 Honors/Fellowships 2007-2008 2008-2010 2010-2013 2013- 2013- Naruo Yoshimura, M.D. Takayasu Kurata, M.D.
Senior InternalMedicineScholarship,UofMichiganMedicalSchool,MI Graduated withdistinction,UniversityofMichiganMedicalSchool,MI Philadelphia, PA Philadelphia, PA Fellow MedicalOncologyMemorialSloanKetteringCancerCenter, NY, NY Center, NY, NY Magna CumLaude-CornellUniversity Vida Scholarship,UniversityofMichiganMedicalSchool, MI Alpha OmegaAlpha,UniversityofMichiganMedical School,MI Chief Fellow, MemorialSloanKettering CancerCenter, NY Penn.,of University the of Hosp. Medicine Internal Intern Penn., of University the of Hosp. Medicine Internal Resident Instructor MedicalOncologyWeillCornell College Attending Medical Oncology Memorial Sloan Kettering Cancer Kettering Sloan Memorial Oncology Medical Attending Abstract
(Kansai Medical University)
(Osaka University) City th -
37
Session ５ - - - - , Kazuki 1 , Takao Tamura 1 . (Osaka City University) (Osaka
, Naoki Takegawa 1 (Osaka Medical Center for Cancer and CVDs) and Cancer for Center Medical (Osaka
1 Abstract , Hisato Kawakami Kinki University , Osaka , Japan Kinki University , Osaka Graduate School of Medical Science , Kinki University Faculty of Medical Center Junior Resident , Akashi Center Medicine , Akashi Medical Senior Resident , Internal Assistant Professor , Department of Medical Oncology , Nara Assistant Professor , Department of Medical Oncology , Kinki Medicine Faculty of Medicine , Nara , Japan Hospital Kinki University University Faculty of Medicine 1
Department of Radiation Oncology, Kinki University Faculty of
2 Tatsuya Ioka, M.D. Ioka, Tatsuya Masakazu Yashiro, M.D. Yashiro, Masakazu 2000-2007 2014-present Research and professional experience 2007-2010 2010-2011 2010-2014 present 2014- Education , Shinya Ueda , Kazuhiko Nakagawa 1 2 Between January 2008 and December 2014, 66 patients with stage IV esophageal
Gastrointestinal Oncology persons, Chair Esophageal cancer is the eighth most frequently diagnosed cancer worldwide, and because of , Masayuki Takeda Palliative chemoradiotherapy combined with irradiation effectively improved the symptom of 1 , Yasumasa Nishimura , Yasumasa 2 Median patient age was 66 years (43 - 78). Three patients had adenocarcinoma, 57 were male, 60 6 Hiroto Ueda, M.D. Ueda, Hiroto Session Department of Medical Oncology, and Clinical significance of concurrent chemoradiotherapy for advanced esophageal cancer esophageal advanced for chemoradiotherapy concurrent of significance Clinical Hiroto Ueda dysphagia in Stage IV esophageal cancer with acceptable toxicity and favorable survival. dysphagia in Stage IV esophageal cancer with acceptable toxicity and plete response. The median survival time was 340 days. 1-year-survival rate was 36.4%. Median progression- were generally tolerable. free survival was 175 days. Toxicities Conclusions: Results: were ECOG PS 1. Median chemotherapy cycle was 3 (1 - 6). Dysphagia score improved in 62.1% of the tients. pa Disease control rate of the primary lesion was 83.3%, including five patients (7.6%) achieved a com Patients Patients and Methods: retrospectively analyzed. cancer treated with platinum, 5-fluorouracil, and concurrent TRT were tom of esophageal cancer. Patients with Stage IV esophageal cancer who had dysphagia, were treated em pirically palliative chemoradiotherapy. The aim of this retrospective study was to provide basic data on the cancer efficacy and toxicity of palliative chemoradiotherapy in Stage IV esophageal Background: common cause of cancer-related death. its poor prognosis it is the sixth most Dysphagia, which means difficulty in swallowing food and liquids, is the most common and serious symp Medicine, Osaka-Sayama, Osaka, Japan Ishikawa 1 38
Session ６ PD, whichsuggests thatwemayneedto developnewtreatment strategies. of time the at persisted effects anti-angiogenic the However, outcome. treatment with associated not were Conclusions: change oflungmetastases persistedwithoutrefillingin84.6%(11/13)ofpatients. according toRECIST1.1,tumor attenuationwaslowerthanbaselinein86.0%(43/50)ofpatients andcavitary (PD) disease progressive of time the At survival. overall or survival, progression-free rate, control disease with associated was changes radiological the of Neither size. cavity pre-existing in increases had 6 and patients 15 in observed was cavitation New treatment. after changes cavitary developed (32.1%) patients 17 with changes in mSUVin PET-CT scans (Pearson’s r=0.38, p<0.001). Among 53 patients with lung metastases, associated modestly were changes attenuation Lesional 20.7%). to -61.5% (range -23.9% was attenuation tumor in change Median attenuation. tumor in decrease a had patients of 87.5% treatment, regorafenib Results: imageswereavailableforanalysis. tomography (PET)-CT emission positron 18-fluoro-deoxyglucose whose patients in analyzed were treatment of cycles 2 after and baseline at lesions tumor of (mSUV) values uptake standardized Maximum regorafenib. with treated (N=80) cavitary changes of lung metastases were analyzed in association with treatment outcome in mCRC patients and scan (CT) tomography computed contrast-enhanced of (HU) units Hounsfield by measured attenuation Tumor (NCT01996969). Study Explorative Prospective A Cancer: Colorectal Refractory in Regorafenib Methods: However, clinicalimplicationofthechangesisunclear. Introduction: Hospital, Seong-nam,Korea Korea; Seoul Hospital, University of Department Won Lim Yoojoo Clinical implications of regorafenib of anti-angiogenic in metastatic effect colorectal cancer Session Yoojoo Lim, M.D. 4 6 , GyeongHoonKang A total of 141 lesions in 72 patients were analyzed with HU measurement. After 2 cycles of cycles 2 After measurement. HU with analyzed were patients 72 in lesions 141 of total A All patients were a part of a main study entitled Identification of Predictive Biomarker of Biomarker Predictive of Identification entitled study main a of part a were patients All 1 , Sae-Won Han Sae-Won , Regorafenib showed prominent anti-angiogenic effect in colorectal cancer, but the changes the but cancer, colorectal in effect anti-angiogenic prominent showed Regorafenib Regorafenib induces distinct radiological changes that represent its anti-angiogenic effect. anti-angiogenic its represent that changes radiological distinct induces Regorafenib 1 Chair persons, Oncology Gastrointestinal Internal Medicine, Internal 4 , Seung-Yong Jeong 1 , Jeong Hee Yoon Hee Jeong , Education Sep 2014-present Mar 2008-Feb2009 Mar 2009-Feb 2012 Mar 2013-present Training Mar 1999-Feb 2004 Mar 2004-Feb 2008 Sep 2011-Jun 2013 6 Masakazu Yashiro, M.D. Tatsuya Ioka, M.D. 2 Department of Internal Medicine, Seoul National University Bundang University National Seoul Medicine, Internal of Department Radiology, 2 5 , Jeong Min Lee Min Jeong , , KyuJooPark 3
Nuclear Medicine, Nuclear
Abstract
University Hospital,Seoul,Korea Hospital, Seoul,Korea University National Seoul Medicine, Internal of Department National University, Seoul,Korea Korea Korea Seoul, University, National Seoul School, Graduate Medicine, National University, Seoul,Korea Seoul School, Graduate Medicine, of Department Oncology, Student under Ph.D. program, Molecular and Clinical and Molecular program, Ph.D. under Student Intern, SeoulNationalUniversityHospital,Seoul, Korea National Seoul Medicine, Internal of Department Resident, of Department Oncology, Clinical and Molecular M.Sc., Fellow, Division of Hematology and Medical Oncology, Medical and Hematology of Division Fellow, Seoul Administrations Business and Education English B.Sc., Seoul, Medicine, of College University National Seoul M.D., 5
(Osaka Medical Center for Cancer and CVDs) , Kyung-HunLee 2 , Jung Min Lee Min Jung , 4
Pathology and Pathology (Osaka University) City 1 , JeeHyunKim 3 , Jin Chul Paeng Chul Jin , 5 Surgery, Seoul National Seoul Surgery, 6 , Tae-You Kim 3 , Jae-Kyung , 1 39
Session ６ . .
1 (Osaka City University) (Osaka .
(Osaka Medical Center for Cancer and CVDs) and Cancer for Center Medical (Osaka
Abstract , and Kazuhiko Nakagawa 2 Resident Konan hospital, Japan Resident Konan hospital, Hospital, Japan Kobe Century Memorial Hyogo cancer center Department of Medical Oncology, Kinki University School of Medicine, Japan
Tatsuya Ioka, M.D. Ioka, Tatsuya Masakazu Yashiro, M.D. Yashiro, Masakazu , Kazuko Sakai 1 2002-2008 University of Fukui Faculty of Medical science 2002-2008 University Research and professional experience 2008-2010 2010-2012 2012-2014 2014-present Education with cetuximab-resistant colorectal cancer colorectal cetuximab-resistant with , Kimio Yonesaka 1
Gastrointestinal Oncology persons, Chair Patients with metastatic colorectal cancer (mCRC) harboring wild-type KRAS benefit from HER2 genomic amplification in circulating tumor DNA from patients patients from DNA tumor circulating in amplification genomic HER2 Analysis of plasma ctDNA by digital PCR could be useful for detecting HER2 amplification in We analyzed plasma ctDNA using digital polymerase chain reaction (PCR) from 18 patients with Our data showed that 22% (4/18) of patients in the cohort exhibited HER2 amplification. One of 6 Session Department of Medical Oncology, Kinki University School of Medicine, Osaka, Japan Kinki University School of Medicine, Osaka, Department of Medical Oncology, Japan Kinki University School of Medicine, Osaka, Department of Genome Biology, Naoki Takegawa, M.D. Takegawa, Naoki Conclusion: patients with CRC who were resistant to anti-EGFR antibody therapy these patients was found to be positive for HER2 amplification in matched tumor specimens collected after cetuximab therapy, at which point the patient had acquired cetuximab resistance, despite being negative for HER2 amplification prior to therapy. resistant cetuximab. HER2 gene copy number was analyzed using fluorescence in situ hybridization in tumor therapy samples before and after acquisition of resistance to cetuximab-based Results: Methods: CRC, who had been treated with anti-EGFR antibody-based therapy (cetuximab) and subsequently acquired mechanisms conferring resistance to anti-EGFR antibody therapy and could therefore be a potential therapeutic target. The aim of this study was to detect HER2 amplification in circulating tumor DNA (ctDNA) therapy from patients with CRC and acquired resistance to anti-EGFR antibody Background: epidermal growth factor receptor (EGFR)-targeted therapy. However, patients who are treated with anti- EGFR antibodies will eventually develop the resistance to those agents. HER2 amplification is one of the 2 Naoki Takegawa 1 40
Session ６ using largersamplesize. evaluated be should circumstance this in MSI of value prognostic and MSI-L/MSS than inferior is CRC MSI-H recurred of prognosis addition, In MSI-L/MSS. of that from different is CRC MSI-H in recurrence of Patterns 0.001]. out recurrence,overallsurvivalwasinferiorinMSI-Htumorpatientswithrecurrence.[HR=3.111,p-value< with patients to contrast In 0.008). p-value 0.0%, vs. (37.1% metastasis lung as recur to likely more is tumor MSI-L/MSS contrast, In 0.033). p-value 7.7%, vs. (25.0% metastasis node lymph and 0.002) p-value 8.0%, vs. (33.3% metastasis peritoneal as recur to likely more is tumor MSI-H 0.001). p-value 6.5%, vs. (13.5% tumor mor. PatientswithMSI-L/MSStumorexperiencedmoresystemicrecurrenceeventsthanpatientsMSI-H tu MSI-H has (8.9%) patients 261 all, Of evaluated. were patients cancer colorectal I-III stage 2942 of total A prognosis afterrecurrencebyMSIstatuswasnotinvestigatedpreviousstudies. Furthermore, investigated. precisely been not has recurrence of patterns CRC, (MSS) stable microsatellite than prognosis favorable more a has (MSI) instability microsatellite with (CRC) cancer colorectal Although 1 Jin Heo Kim Chang-gon Division ofMedicalOncology, Yonsei CancerCenter, 50Yonsei-ro, Seodaemun-gu,Seoul,120-752,Korea Chang-gon Kim, M.D. Kim, Chang-gon Session 6 1 , andJiHyungKim 1 Chair persons, Oncology Gastrointestinal , Sang Joon Shin Joon Sang , Microsatellite Instability in Recurred Colorectal Cancer 1
Education 2005.03-2007.02 2002.03-2005.02 2012.03-2016.02 2011.03-2012.02 TrainingPostgraduate 2013.09-2015.08 2010.01-2010.03 2007.03-2011.02 1 , Joong Bae Ahn Bae Joong , Masakazu Yashiro, M.D. Tatsuya Ioka, M.D.
Abstract 1 , Minkyu Jung Minkyu , of HealthSystem,Seoul,Korea Graduate school,Yonsei University, Seoul,Korea USA Seoul, Korea Myungduk foreignlanguagehighschool,Seoul,Korea Premedical program, college of science, Yonsei University, Yonsei science, of college program, Premedical Resident, Department of Internal Medicine, Yonsei University Yonsei Medicine, Internal of Department Resident, Internship, Yonsei UniversityHealthSystem,Seoul,Korea The Medicine, of Department science, medical of Master College ofMedicine,Yonsei University, Seoul,Korea Sister InstitutionAssociate,M.D.AndersonCancerCenter, TX,
(Osaka Medical Center for Cancer and CVDs) 1 , Seung Hoon Beom Hoon Seung ,
(Osaka University) City 1 ,
Joo Hoon Kim Hoon Joo 1 , Soo , - - 41
Session ６ ＭＥＭＯ
42 ＭＥＭＯ
43 ＭＥＭＯ
44 ＭＥＭＯ
45 Contact : Kinki University Educational Affairs, Training Plan for Oncology Professionals Secretariat Email: [email protected] Fax: 072-366-2103